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ABSTRACT  
   
Auditory hallucinations are a characteristic symptom of schizophrenia. Research 
has documented that the auditory cortex is metabolically activated when this process 
occurs, and that imbalances in the dopaminergic transmission in the striatum contribute to 
its physiopathology. Most animal models have focused the effort on pharmacological 
approaches like non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists to 
produce activation of the auditory cortex, or dopamine antagonists to alleviate it. I 
hypothesize that these perceptual phenomena can be explained by an imbalance 
activation of spiny projecting neurons in the striatal pathways, whereby supersensitive 
postsynaptic D2-like receptor, signaling in the posterior caudatoputamen generates 
activation of the auditory cortex. Therefore, I characterized the neuroanatomical 
component involved in the activation of the auditory cortex. I evaluated the participation 
of dopamine D2-like receptor using selective dopamine antagonist manipulations and 
identified the circuits related to the auditory cortex by retrograde trans-synaptic tracing 
using pseudorabies virus (PRV-152). My results show that dopamine infused in the 
posterior caudatoputamen dose dependently increases the transcription of the immediate 
early gene, zif268 in the auditory cortex, predominantly in layers III and IV, but also in 
cortical columns, suggesting enhanced functional auditory activity. This indicates the 
participation of the posterior striatum in the modulation of the secondary auditory cortex. 
I was able to demonstrate also that a coinfusion of a selective dopamine D2-like receptor 
antagonist, eticlopride and dopamine, attenuate the activation of the auditory cortex. 
Furthermore, using PRV-152 I delineate the distinctive circuit by axial mapping of the 
infected neurons. Thus, I found secondary projections from the posterior caudatoputamen 
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that synapse in the thalamus before reaching the auditory cortex. These striatal 
projections correspond to the same brain region affected by dopamine during auditory 
cortical activation. My results further characterized a mechanism to generate intrinsic 
perception of sound that may be responsible for auditory hallucinations. I propose this 
paradigm may elucidate insight on the biological basis of psychotic behavior. 
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PREFACE 
 Manifestations of psychotic symptoms like auditory hallucinations are an 
interesting ground for research of the neurobiological basis of auditory perception. Our 
understanding of antipsychotics as a model to attenuate endogenous function of the brain, 
and the neuroanatomical knowledge provided by neuronal tracers allow the identification 
of neuronal networks responsible for these psychotic manifestations. Therefore, the 
present work evaluates the pharmacological effect of increased dopamine in the posterior 
caudatoputamen and test the effect of a selective D2-like receptor antagonist in the 
activation of the auditory cortex. This activation was assessed at the level of cortical 
structure to point out the exact location of the effect in the auditory cortex. In this 
manner, the efferent projections towards the highlighted area in the auditory cortex were 
retrogradely traced to establish the multisynaptic circuit involved. Studying the networks 
related to these phenomena will allow a better understanding of the mechanisms that lead 
the brain to generate a false perception of sound and may provide insight of the neuronal 
source of inner speech.  
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CHAPTER 1 
INTRODUCTION 
1.1 Statement of Purpose 
I am a neuroscientist with a medical background interested in the neurobiological 
basis of perception and its alterations in psychiatric disorders such as schizophrenia. My 
main motivation to pursue studies in neuroscience is my fascination for the sophisticated 
circuitry that recreates inside the brain a perception of our surroundings and us. My 
research focuses on the neuromodulation of cortico-striato-thalamo-cortical (CSTC) 
circuits relevant to the physiopathology of auditory hallucinations. These distortions of 
auditory perception produced by psychostimulants or psychotic disorders provide an 
interesting groundwork to study endogenous perception of the auditory modality. 
To achieve my research objectives I joined the laboratory of Dr. Ron Hammer, where I 
developed my dissertation project. The main hypothesis of my research was based on 
three pieces of evidence. The first one is the increased dopaminergic transmission in the 
caudate nucleus shown by patients with schizophrenia; the second one relates to the 
therapeutic effects of antipsychotics through D2-like receptors; and the third one is the 
description of corticostriatal projections from the auditory cortex. 
My research evaluates dopaminergic transmission in the dorsal caudatoputamen of the rat 
as endogenous factor that activates the auditory cortex. I used stereotaxic intracranial 
procedures to infuse dopamine or co-infuse D2-like selective dopamine receptor 
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antagonist in the posterior aspect of the caudate nucleus. In this manner, I was able to 
demonstrate a dopamine-dependent activation of the auditory cortex quantifying changes 
in the expression of the messenger RNA of zif268, an immediate early gene linked to 
neuronal activity. This pharmacological work was presented in the Annual Scientific 
Conference of the Society of Biological Psychiatry (SOBP), where was nominated for 
best presentation because of its ability to translate basic science into concrete clinical 
applications.  
In my research I also describe the brain regions that participate in the neuronal circuit 
responsible for dopamine induced auditory activation. Using pseudorabies virus 152, a 
trans-neuronal retrograde tracer that expresses enhanced green fluorescent protein as a 
marker for trans-synaptic infection, I was able to map multisynaptic projections to the 
auditory cortex that originated in the posterior caudate. These circuits constitute a 
neurobiological measure that relates to a mechanism of psychopathology. Our findings 
contribute; therefore, under the current research domain criteria promoted by the National 
Institute of Mental Health, to define the units of analysis under the construct of network 
disruptions of brain connections. This project provides a new piece of evidence related to 
the existence of an auditory cortico–striato-thalamo-cortical (CSTC) circuit relevant to 
the physiopathology of auditory hallucinations. 
Making use of these findings, I look forward in my career to characterizing the role 
striatal pathways play in the auditory CSTC circuit. I believe it is in these networks of the 
basal ganglia, where information decoded form the auditory sensory system is fitted to 
schemata that contain our perspective of the world. Classically, the striatal pathways are 
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described as direct and indirect, with both pathways integrated at the globus pallidus 
level. In theory, the glutamatergic corticostriatal input they receive generates an 
activation that loops back to the cortex through the thalamus. My strategy consists in 
assessing each portion of the auditory CSTC circuit using recombinant vectors that would 
allow controlling for neuronal populations, hence permitting to elucidate functioning 
patterns at each level of the circuit. A matter for future research is to study endogenous 
inputs to the auditory cortex implementing neuroimaging and electrophysiological 
techniques. Decoding the function of the auditory CSTC circuit will add to our 
understanding of the physiopathology of auditory hallucinations and would assist in the 
development of more accurate interventions for psychotic symptoms.  
1.2 Scope 
Schizophrenia is a conglomerate of mental disorders with diverse clinical course and 
a broad effects in multiple brain functions, which include disturbances of thinking and 
perception, affect and social behavior. The onset of the disease occurs at the beginning of 
adulthood and the prognosis depends on the cognitive and social dysfunction developed 
over the time. Low adhesion to treatment strategies and profound side effects of 
antipsychotics usually generate patients with high dysfunctional lifestyle; therefore, 
schizophrenia is a major concern in public health worldwide Barbato (1996). Beyond the 
comorbidity and social cost of schizophrenia, the disease provides a fascinating scenario 
to study the source of endogenous sound perception (Waters et al., 2006).  
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In psychotic disorders, hallucinations can have complex sensory components. The visual 
and somatosensory modalities may participate in these phenomena, though verbal 
auditory hallucinations are most frequent in the description to the physician (Lecrubier et 
al., 2007). The effects on brain circuits involved in auditory perception leading to a false 
sound perception emphasize that research on these phenomena may provide a mechanism 
of intrinsic perception of sound that not only bring insight of the physiopathology of the 
disease but also show the brain interaction that allows us to generate thought and interpret 
the world.  
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CHAPTER 2 
BACKGROUND LITERATURE 
2.1 History of Schizophrenia 
Bleuler first named schizophrenia in 1908, and since its diagnosis has depended 
on the clinical anamnesis. The word comes from the greek roots schizo-phrene, which 
mean split- mind. Patients with schizophrenia usually have a heterogeneous 
manifestation composed of three arrays of symptoms: positive, negative and cognitive 
(Liddle, 1987), which depict the excitation or inhibition of different neuronal 
networks.  
There have been descriptions of psychotic symptoms since the times of ancient 
Egypt. Although the population has been aware of mental illness throughout history, 
it was not until a description by Kraepelin in 1887 that schizophrenia could be 
differentiated from other mental disorders. In his description Kraepelin referred to the 
disease as dementia praecox, an early onset compared to other types of dementia 
characterized the syndrome that will be better characterize in 1911 by Bleuler.  
Initially, some major features seen in schizophrenic patients were classified into 
paranoid, disorganized, and catatonic. These subtypes were later included in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-III) with the addition of 
the residual and undifferentiated subtypes. The evaluation of clinical observations has 
changed over time allowing for few modifications in the DSM-IV and recently DSM-
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V, but a biological basis for schizophrenia is still elusive from the clinical 
classification. This has led to a low correlation of prognosis and the appropriate 
therapeutic for each subtype. As a result, the National Institute of Mental Health 
proposed an initiative to reclassify the symptomatology of schizophrenia following 
units of study from genes to behavior under the constructs of mental systems involved 
(Miller, 2010). This approach called research domain criteria allows a better match to 
our understanding and focus research into a more effective classification of the 
disease.  
2.2 Epidemiology 
It is estimated that 29 million patients have schizophrenia of which only 9 million 
are located in developed countries. Such difference in the distribution has been 
explained by factors that affect the prevalence since an incidence of 0.1 to 0.4 cases 
per 1000 people is consistent in different regions despite socioeconomical variables 
(Jablensky et al., 1992); thus, the effect of health care, minority groups and access to 
development shows a lifetime prevalence that varies between 1 to 18 cases per 1000 
people worldwide (Warner, 1995). Places with wider variation in the prevalence of 
schizophrenia also showed a long-term decrease as developing countries provide 
better care that improves the outcome of patients (Warner, 1995). Places with wider 
variation in the prevalence of schizophrenia also showed a long term decrease as 
developing countries provide better care that improves the outcome of patients (Leff 
et al., 1992). As a result, symptomatic treatment for schizophrenia may improve 
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symptoms in places of high prevalence though the cause of this disorder is still not 
tackle by any of the current therapeutics. 
An accurate estimation of the costs can only derive from reliable data in developed 
countries. In the United States, a total annual cost of $32.5 billion that accounts for 
$17.3 billion of direct cost, $12 billion of indirect cost and $3.2 billion in other 
related costs (Knapp et al., 2004). Those figures depict the immense impact of 
schizophrenia in society.  
Risk factors for schizophrenia can be group into sociodemographic, predisposing and 
precipitating aspects of the disease. They show the role of social environment in the 
manifestation of psychotic episodes. In the sociodemographic factors, unmarried 
individuals have four times a higher risk of presenting psychotic episodes. In 
addition, a lower social class has a strong correlation in western countries with 
schizophrenia. The genetic component while still elusive is the predisposing factor of 
more relevance. Recent research demonstrates that at least 17 different genotypes 
contribute to the disease, which result in the expression of eight phenotypes sets. The 
association and interaction between the genotypes and phenotypes seems to 
contribute for up to 60% of cases (Arnedo et al., 2014). Some other insults like birth 
complications have shown a lower correlation to explain the disease. On the 
precipitating factors a less supportive family with negative affective interactions and 
fragmented communication are the most relevant not only for initiating a first 
psychotic episode but also in relapse and chronic manifestations (Miklowitz, 1994). 
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2.3 Clinical definitions and diagnosis 
The DSM has presented different characterizations of the disease. The latest 
version, DSM-5, attempts in this manner to bring research domain criteria to allow 
understanding of the disorder based on the neuropathology (Bhati, 2013).  Thus, the 
differential diagnosis of schizophrenia requires considering six criteria: 
A. The characteristic symptoms like delusions, hallucinations, disorganized speech, 
disorganized or catatonic behavior and negative symptoms like affective flattening, 
alogia and avolition must be predominant for more than a month with at least two of them 
present to fulfill criterion, or less if successfully treated (APA, 2013) 
B. Social and occupational dysfunction is another criterion whether loss of self-care, 
interpersonal relations or work activities from the level previously accomplish, or in the 
case of early onset schizophrenia the lack of achieving the level according to the current 
age of onset.  
C. Duration of six month is required where symptoms fluctuate between positive, 
negative or cognitive symptoms. 
D. Exclusion criteria include:  
a. Mood disorders during the onset of the disease must be evaluated as some 
major mood disorders or schizoaffective disorder may manifest similar clinical frames. 
This particular exclusion denotes how some patients have a disease that involves circuits 
relevant to other brain functions like amygdala.  
  9 
b. Substance abuse or medications that produce psychotic acute syndromes 
are other consideration for differential diagnoses. Most of these drugs are 
psychostimulants like phencyclidine or ketamine, which may reproduce similar case by 
enhancing cortical activation (See section on psychostimulants)  
c. Global developmental delay or Autism spectrum disorders are other 
differential diagnosis. Schizophrenia could be considered in this case additional diagnosis 
when predominant delusions or hallucinations step on the previous diagnosis.    
2.3.1 Course of the disease 
The first consultation usually appears during the manifestation of a positive phase that 
entails delusions, hallucinations, disorganized speech or catatonic behavior. The course 
of the disease continues with negative phases that are normally composed by affective 
flattening, alogia or avolition. The presence of these negative symptoms is associated 
with the disease detriment in cognitive function characterized by lack of attention, 
executive function and problems with working memory (McGorry et al., 2002). 
Symptoms of this nature appear combined in most cases given the disease multistage 
record; nevertheless, poor prognosis is related to accentuate negative phases and an early 
onset of the disease (Rund, 1998). In this manner, the manifestations vary between a 
paranoid phase characterized by positive symptoms, a disorganized phase with cognitive 
detriment, an undifferentiated phase composed of a mix of positive and negative 
symptoms and a residual phase were negative symptoms are predominant. These clinical 
phases may vary in their intensity or according the patient´s response to treatment. The 
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current estimate of medium-term course shows 45% recover after the initial episode, 20% 
have a constant phase that do not improve and 35% have a fluctuating disease course 
with periods of remission and illness.  
The duration of an acute stage may vary between patients as well as the frequency of 
these episodes, which are present throughout a lifetime. In many cases, there is a 
prodrome stage, where positive symptoms are not pronounced, and in which diagnosis 
has proven elusive. Although negative symptoms precede frequently cognitive deficit, 
vocational and social disabilities of patients are predicted by cognitive dysfunction 
having a short-term memory detriment and attentional deficit a main participation (Green, 
1996). The content of positive symptoms is associated with the level of education, which 
may produce sophisticated delusions or hallucinations described as Schneider´s first rank 
symptoms (Crow, 1980). Different cultural backgrounds may initially disclose other 
mental affections as major complaint covering the actual beginning of the disease, which 
can start as early as six years of age. Nonetheless, 70% of cases present auditory 
hallucinations, which make of this symptom important tool for diagnosis (Barbato, 1996). 
Therefore, the clinical features of auditory hallucinations are relevant to evaluate the kind 
of brain insult that generates these phenomena; therefore, research in auditory 
hallucinations may also uncover the brain regions and synaptic changes underling the 
neuropathology of schizophrenia like symptoms.  
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2.4 Auditory hallucinations 
The false perception of sound described in psychiatric cases, as an additional 
voice perceived separated from the mental process is the most common way of 
presentation. However, other mental disorders that can exhibit auditory hallucinations are 
bipolar disorders with a 20-50% prevalence and posttraumatic stress disorder with 40% 
prevalence (Choong et al., 2007).  Location, self-other attribution and language 
complexity are the clinical aspects evaluated of auditory hallucination (Stephane et al., 
2003). Other characteristics like duration, frequency and intensity that are part of the 
anamnesis assessment have not related to the brain regions affected. In this manner, the 
perceived location of the hallucination can clinically be described as the hallucination 
heard from outside the head of the patient or heard from the inside (Bleuler and Bleuler, 
1986). The right temporoparietal junction has shown anatomical differences in these 
patients compared to healthy controls. Brain imaging studies have also shown changes in 
the left temporal cortex and Broca’s area in patients with verbal auditory hallucinations 
(Silbersweig et al., 1995, Cachia et al., 2008), while changes in the cingulate and 
temporal cortices are associated to self-other misattribution (Hubl et al., 2004, Allen et 
al., 2007). Research on the neuroanatomical input of the auditory cortex has shown two 
different pathways one ventral and another dorsal (Rauschecker and Tian, 2000).  The 
parietal region and superior temporal gyrus appear to be the coalescent point for both 
pathways (Altmann et al., 2007). Based on these findings the secondary auditory, 
prefrontal, cingulate, subcortical regions demonstrated changes in patients with auditory 
hallucinations (Allen et al., 2008). The limitations to the study in human brain and the 
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nature of subcortical regions makes this area to remain unclear; however, the bilateral 
thalamus, right putamen and caudate, bilateral parahippocampus, cingulate and 
orbitofrontal cortex appear to be associated with auditory hallucinations (Silbersweig et 
al., 1995).  
2.4.1 Brain activity during auditory hallucinations 
The functional study of the brain utilizes non-invasive procedures to evaluate the 
electric activity of the brain. For example, electroencephalographic variations or the 
oxygenation level in blood like in the functional MRI and PET are used to assess the 
level of metabolic activity of the nervous tissue (Font et al., 2003). In animal models, 
techniques with higher resolution and greater detail have been used to evaluate the 
expression of functional markers in the tissue and the electric activity of the neurons in 
specific brain regions.  
Human studies evaluated the activity of brains during hallucinations or their 
performanceon verbal task compared with healthy controls (Lahti et al., 2006). From 
these studies, the temporal cortex is consistently highlighted and haves shown that 
different regions of the temporal cortex are responsible for different features of sound. 
For example, Alemann et al. using electroencephalographic recordings suggested that the 
anterior aspect of the superior temporal lobe has a role in sound identity while the 
posterior aspect is in charge of the spatial processing. In animal models, aberrant 
dopaminergic transmission seems to play an important role (Carlsson, 1988). The 
interaction between auditory related regions on animal models suggests lack of cerebral 
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inhibition and abnormal excitation during auditory hallucinations (Weiss and Heckers, 
1999). It has been suggested, therefore, that the cortical activity provides the specific 
signal information of the perceptual content whereas activity in deep brain structures may 
modulate recognition of auditory patterns or produce auditory hallucinations (McGuire et 
al., 1995).  
The treatment of auditory hallucinations depends on the interference and intensity of 
these phenomena in normal life, as well as other clinical manifestations that accompanied 
it in psychotic and organic conditions like trauma and tumors. When auditory 
hallucinations are intrusive and require control, antipsychotics are the usual treatment 
(Shergill et al., 1998) though transcranial magnetic stimulation has been used as adjuvant 
(Hoffman et al., 2005, Aleman et al., 2007). These measures address in part the 
modulation of the activity in the auditory cortex and language cortical regions; 
nevertheless, the action of antipsychotics is been debated since they are systemically 
administer acting in various brain regions and they have multiple receptors sites.  
2.5 Antipsychotic drugs 
The use of antipsychotics started in 1952 with the use of chlorpromazine in the 
Central Military Hospital by Drs. Hamon, Paraire and Velluz as well as in the Sainte-
Anne Hospital by Dr. Deniker and Harl (Lopez-Munoz et al., 2005). This phenothiazine, 
synthesized by Charpentier in 1950 was initially used as anesthetic (Swazey, 1979). The 
search for antimalarial compounds in World War II had led to the implementation and 
synthesis of aminoalkyl chains (Gilman and Tolman, 1946). These antihistamines 
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developed as antimalarial drugs found good use as adjuvant for anesthesia before their 
antipsychotic effects were described by Laborit and Huguenard in 1951 (Laborit and 
Huguenard, 1951). More than forty phenothiazines were developed since 1960s by 
Rhône-Poulenc, but only fluphenazine and haloperidol were available in the US (Shen, 
1994).  Due to the side effects, especially extra pyramidal symptoms, clozapine was 
developed in Switzerland by Wander Pharmaceutics (Hippius, 1989); however, 
prescription was limited due to the report of agranulocytosis as side effect (Bailey, 1997). 
In this manner, other drugs derivate from the latter class of antipsychotics were 
developed. These, atypical antipsychotics work through mixed receptor antagonism and 
produce low extra pyramidal symptoms.    
Most treatments that have demonstrated effectiveness alleviating psychotic symptoms 
have effects on the dopaminergic transmission in the brain. Specifically, the D2-like 
receptors in the mesolimbic and nigrostriatal brain areas (Seeman et al., 1975). Clinical 
treatment schemes show improvement in 75% of acute patients over 6-14 weeks with 
300-750 mg of chlorpromazine equivalents (Dixon et al., 1995); thus, these medications 
help to improve symptoms and prevent recurrence of acute psychotic syndromes (Lewis 
and Lieberman, 2000). Nonetheless, 30% of acute patients will not response to 
antipsychotics, and 60% of chronic patients will not have improvement on negative and 
cognitive symptoms (Miyamoto, 2002).  
This family of drugs has grown in recent years leading to their classification into 
conventional and atypical antipsychotics. Conventional antipsychotics come from five 
groups of molecular structures Phenotiazines, Thioxanthenes, Butyrophenones, 
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Dibenzoxazepines and Dihydroindolones, which block dopamine receptors as a 
mechanism of action (Freedman, 2003). These medications also share side effects in 
different systems that involve in the central nervous system sedation and extrapyramidal 
symptoms like tremors, dystonias, akathisia, akinesia, stiffness and shuffling gate. 
Endocrine side effects like amenorrhea, galactorrhea, ginecomastia and weight gain. 
Anticholinergic effects like constipation, blurred vision and dry mouth. In addition, skin 
and eye side effects like cutaneous rash, phototoxic skin reaction and granular deposits in 
the cornea (Lieberman et al., 2005). Consequently, newer antipsychotics attempt to 
eliminate these side effects acting in other neuromodulators besides dopamine receptors 
or having a more selective interaction with dopamine.  
The current indication for conventional antipsychotics is patients that respond with few 
side effects, and those that will require short or long intravenous medication. 
Nonetheless, chronic treatments will require higher doses due to up-regulation of D2-like 
dopamine receptors (Florijn et al., 1997, Kapur et al., 2000) and adjuvant medications to 
control comorbidity. As atypical antipsychotics become available in other ways of 
administration besides of the oral route, the tendency is to use atypical antipsychotics as 
first line of treatment.   
2.5.1 Mechanisms of conventional antipsychotics 
The mechanism of conventional antipsychotics brought research to evaluate the 
presynaptic and postsynaptic targets of these molecules. In the first scenario, the 
hypothesis that antipsychotics may affect at the presynaptic level the release of dopamine 
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was first study by Seeman & Lee in 1974. They found in nerve terminals that the dose of 
haloperidol necessary to increase dopamine release was a hundred times more than the 
clinical concentration measure in cerebrospinal fluid (1 – 4 nM), and that 
chlorpromazine, a more potent antipsychotic required a thousand times the observed 
clinical dose. Moreover, the presynaptic effect of antipsychotics to block the release of 
dopamine also requires higher doses of approximately ten times of those observed in the 
spinal fluid. In this way, the role of antipsychotics in modifying the release of dopamine 
with a presynaptic target was rejected.  
Another hypothesis evaluated the action of antipsychotics in the postsynaptic portion of 
dopaminergic synapses.  The effects on dopamine-stimulated adenylate cyclase were also 
rejected not only for the higher doses require but also because of the lack of correlation 
with the clinical potency. However, the relationship between clinical potency of 
antipsychotics and the displacement of the binding of [3H]-haloperidol provided the 
strong evidence that in striatal membranes there was a common target for all 
antipsychotics. This target was later confirm to be a dopaminergic receptor when the 
affinity of dopamine changed the binding of [3H]-haloperidol more than any other 
neurotransmitter. Likewise, a stereo-selectivity of this binding was assessed by 
comparing [3H]-haloperidol with [+] and [-] butaclamol, which does not have therapeutic 
effects though it bind dopamine receptors. With the use of more selective radioactive 
molecules, dopamine receptors were classified into two families D1-like and D2-like 
dopamine receptor (Kebabian and Calne, 1979) of which a dopamine D2-like receptors 
were the common target of the conventional antipsychotics (Seeman et al., 2002). The 
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exact location of the effect of D2-like receptors has brought more considerations as D2-
like receptors were found to in the presynaptic and postsynaptic sites (Bloom et al., 
1965).  
2.5.2 Mechanisms of atypical antipsychotics 
The side effects produce by conventional antipsychotics favor the search for new 
agents with less extrapyramidal effects, dyskinesia and lower prolactinemia while greater 
therapeutic effects. Atypical antipsychotics still have other side effects; however, like 
weight gain, hyperglycemia and dyslipidemia. Their broad pharmacological profile is still 
under research, but these new drugs are commonly the first line of treatment in acute 
psychotic cases (Buckley, 2001, Kane et al., 2003, Miyamoto, 2003). Atypical 
antipsychotics target multiple neurotransmitters, which provide more mechanisms of 
action; therefore, we will consider them separately to see each profile.  
D2 receptor antagonism: Benzamides have high affinity for D2-like receptor and low D1-
like receptors. Part of these drugs are Amisulpride and sulpride, which show a 
presynaptic effect at low doses that generates release of dopamine, but a postsynaptic 
effect that associates with antipsychotic action at high doses. Benzamides are 
characterized for a fast dissociation of D2 receptors and prefer occupancy of limbic 
targets (Bressan et al., 2003). Amisulpride is indicated in acute phases at doses of 400 – 
800 mg /day as well as in the management of negative symptoms with doses of 50 to 300 
mg / day (Curran and Perry, 2001). Due to their action on D2-like receptors, benzamides 
are thought to stabilize the effects of endogenous dopamine toward striatum; therefore, 
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they are also used in the treatment of mood disorders like bipolar disorder and dysthymia. 
Common side effects of benzamides include extrapyramidal effects like dystonia, tremor, 
akathisia and parkinsonism. Less common side effects are hyprolactinemia, 
hypersalivation, anxiety and weight gain. Overdose of benzamides produce 
electrocardiographic changes like torsades de pointes. Due to their effects in the heart, 
benzamides should not be used in patients with long QT segment, low heart rate or 
hypokalemia. Benzamides are not metabolized in the liver, and excreted by the kidney in 
a 23 %– 46 %, they have interactions with other medicines like tricyclics and other 
antidepressants, and clozapine.  
D2 receptor partial agonism: Aripiprazole has an interesting D2-like receptor profile 
because of the affinity for the receptor as agonist and antagonist. It also interacts with 
serotonin receptors having agonistic effects on 5-HT1A and antagonist action on 5-HT2A 
(Shapiro et al., 2003) as well as low affinity for histamine and cholinergic receptors. This 
has been studied in animal models where aripiprazole stabilizes the dopaminergic system 
through selective activation of D2-like receptors (Lawler et al., 1999). Evidence on 
aripiprazole is not consistent for long term use because in maintenance treatments with 
doses of 10 to 30 mg / day extrapyramidal symptoms are develop over time (Khanna et 
al., 2014). However, aripiprazole has also been used in major depression and autism 
because its ability as mood stabilizer. The liver metabolizes aripiprazole and medicines 
that affect the activity of CYP2D6 and CYP3A4 enzymes interfere with its 
bioavailability.   
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Serotonin receptor 5-HT2A antagonism: clozapine and its derived drugs risperidone, 
olanzapine and ziprasidone are 5-HT2A receptors antagonist. It is believe that these drugs 
increase the release of glutamate in prefrontal cortex (Aghajanian and Marek, 2000). The 
high occupancy of serotonin receptors by this compounds correlate with their therapeutic 
effects although all of them show some antagonist profile with D2-like receptors as well 
(Farde et al., 1995, Kapur et al., 1998).  Clozapine is used as second line of treatment 
when symptoms are resistant in schizophrenia. It is also helpful in the treatment of 
schizoaffective syndrome as antipsychotics. The major side effect of clozapine is 
agranulocytosis, which occurs in 1 % of the patients regularly after three months of use. 
Therefore, the first six months patients taking clozapine need to have their blood counts 
checked. Other less frequent side effects of clozapine include cardiac toxicity, 
gastrointestinal hypomobility and hypersalivation. Interactions with quinolones and 
benzodiazepines prevent the use of clozapine with these medicines. The liver highly 
metabolizes clozapine through the cytocrhome P450, therefore it has a first-pass 
metabolism that limits its bioavailability to 60 %. The dosage of clozapine varies between 
12.5 to 400 mg per day. Due to the effects of clozapine in other neurotransmitter systems, 
its effects as antipsychotic not only depend on the serotoninergic system; nonetheless, the 
improvement of cognitive and negative symptoms seem to be related to the facilitation of 
cortical glutamatergic release as outcome on other neurotransmitters. 
Serotonin receptor 5-HT1A partial agonism: These agents may reduce the release of 
glutamate  on pyramidal cells (Aghajanian and Marek, 2000). Though they may 
contribute to mood disorders, in psychotic cases their pharmacological profile makes 
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them useful as adjutants through potentiation of dopamine antagonists or decrease of 
extrapyramidal effects (Lucas et al., 1997). Azapirone and buspirone are used in the 
treatment of anxiety disorders and depression. Some side effects are restlessness and 
dizziness but do not present the potential for drug abuse or addiction as benzodiazepines 
or other mood stabilizers.  
Modulation of glutamate receptors: Allosteric agonists of the NMDA receptor provide in 
animal models improvement of parameters for negative and cognitive symptoms (Goff 
and Coyle, 2001). There are four ways to affect the glutamatergic system: glycine 
reuptake inhibitors, glutamate reuptake inhibitors, metabotropic receptor agonists and 
AMPA/kainite receptor antagonist. The first and second ones are inhibitors of excitatory 
neurotransmitters, which may affect trafficking of glutamate receptors specifically in the 
prefrontal cortex, basal ganglia and hippocampus (Bergeron et al., 1998). The third 
mechanism refers to the presynaptic receptors mGlu group II, which regulate release of 
glutamate. Agonist of this group of receptors, especially mGluR5 decreases glutamate 
release and have antipsychotic activity (Rowley et al., 2001, Chavez-Noriega et al., 
2002). Lastly, the AMPA/Kainate receptor antagonism has shown to improve deficits on 
working memory probably through increase of glutamate release (Svensson and Mathe, 
2000). Nevertheless, the development of drugs for treatment use is still under research, in 
part due to the complex function of the NMDA receptor with multiple binding sites.  
Norepinephrine receptors: Agonists of the alpha-2 postsynaptic receptor have 
demonstrated to improve cognitive deficits (Fields et al., 1988) through their action in the 
prefrontal cortex; therefore, clonidine or guanfacine have been used as adjuvant drugs in 
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the treatment of cognitive dysfunction. On the contrary, antagonists of the alpha-2 
receptor like idazoxan enhance cortical release of dopamine reproducing the 
antipsychotic action of clozapine when it is administer in conjunction to dopamine 
antagonists (Millan et al., 2000).  
Nicotinic acetylcholine receptors: Stimulation of these receptors in the prefrontal cortex 
improve cognitive function by acting on the alpha-7 subunit type (Rezvani and Levin, 
2001) and also sensory gating through alpha-4-beta2 agonism (Schreiber et al., 2002). 
Muscarinic receptor agonists had antipsychotic action through M1 cholinergic receptor, 
which improves cognitive function, negative symptoms and affective disorders (Bymaster 
et al., 2002). 
2.6 Dissociative Anesthetics Drugs 
Other compounds that stimulate the glutamatergic system can cause 
schizophrenia-like symptoms. The interaction that some antipsychotics have with 
noncompetitive NMDA receptor antagonists has brought the hypothesis that this receptor 
may participate in the neuropathology (Olney and Farber, 1995). Therefore, 
phencyclidine (PCP) and ketamine are commonly used in animal models. They can 
reproduce correlates of the positive- and negative-like schizophrenia symptoms as well as 
cognitive deficits in standardize animal paradigms. The hypothesis has been tested on 
pharmacological models where 5-HT2A antagonist recover the deficit on prepulse 
inhibition (PPI) induced by PCP; similarly to D2-like antagonist (Wang and Liang, 
1998). In addition, 5-HT2A antagonists recover the metabolic activation of prefrontal 
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cortex generated by ketamine (Duncan et al., 2003). Although the mechanism by which 
PCP and ketamine produce dissociative effects in humans and deficits in cognitive and  
sensory gating function is not well understood,  a possible explanation attributes a high 
function of NMDA receptor in the prefrontal cortex; hence, the specific acute effect of 
NMDA antagonist in attenuating symptoms and improving the deficits in animal models 
(Coyle, 1996).  
2.7 Dopamine 
Kathleen Montagu first described dopamine in 1957, and its relevance in the brain 
came to light when it was found diminished in the brains of patients with Parkinson’s 
disease (Ehringer and Hornykiewicz, 1960). This finding was later related to 
schizophrenia as patients receiving conventional antipsychotics developed Parkinsonism. 
In this manner, increased dopamine transmission in the striatum has been reported in 
schizophrenia patients with the use of radiotracers to evaluate the availability of D2-like 
receptors (Abi-Dargham et al., 2012). The action of dopamine has been related to 
motivation, reward and reinforcement of learning. This catecholamine is produced in the 
substantia nigra and ventral tegmental area of the brain. From these areas of the 
mesencephalon dopamine is release in the cortex and basal ganglia, of which the striatum 
is a major target. Dopamine is produced from tyrosine by the tyrosine hydroxylase and 
DOPA decarboxylase steps. Once release, dopamine is removed from the synaptic area 
by dopamine transporters and deactivated by monoamine oxidase and catechol O-methyl 
transferase. Dopamine acts in the nervous system through G protein -coupled receptors in 
the presynaptic and postsynaptic sides. 
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2.7.1 Dopamine receptors 
Projections from the substantia nigra pars compacta located in the mesencephalon 
are responsible for the release of dopamine in the dorsal striatum (Grace, 1991, Bolam et 
al., 2000). In the striatum, dopamine receptors presynapticaly regulate glutamatergic 
cortico-striatal projections (Bamford et al., 2004b), and postsynaptically modulate the 
phasic GABAergic firing of spiny projecting neurons (SPNs) (Surmeier et al., 1996).  
The class of G protein these receptors are coupled to determines the action of dopamine 
binding receptors in SPNs. In this manner, dopamine receptors can be classify into D2-
like receptor (D2R) – which interacts with G i/o hence decreasing the probability of SPN 
firing – and D1-like receptor (D1R) – which interacts with G s/olf, hence increasing the 
firing rate (Surmeier et al., 2007).  
The downstream effect of these G  proteins can affect glutamate receptor trafficking and 
the metabolic state of SPNs. Activation of G s by dopamine D1-like receptor, increases 
phosphorylation through a cascade that involves adenylyl cyclase activity; therefore, 
increasing cAMP and protein kinase A. On the contrary, activation of G i by D2-like 
receptors decreases phosphorylation through the same cascade but with the opposite 
effects. This regulation of phosphorylation has related dopamine receptors to the firing 
probability of SPNs through their action on inward rectifying potassium current channels 
(Kir K+). Kir2-4 K+ channels normally hold the membrane potential about -90 mV in 
typical of SPNs. When they are inactivated by D1-like receptors downstream effects, 
there is an elevation of the membrane potential that facilitates neuronal firing (Day et al., 
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2008), which produces an up state. The action of D2-like receptors prevents this up-state 
and facilitates a down state by acting on L-type Ca2+ (Cav1) and Na+ channels (Nav1) 
that increases hyperpolarization reducing the firing of SPNs (Olson et al., 2005). 
The effects of dopamine receptors in glutamate transmission can be presynaptic or 
postsynaptic. D2-like presynaptic receptors can mediate release of glutamate in 
corticostriatal projections or affect glutamate receptors activation by dephosphorylation 
of GluR1 subunits (Hakansson et al., 2006). On the postsynaptic side, dopamine D1-like 
receptors may generate mobilization of AMPA and NMDA receptors increasing their 
expression in the synaptic cleft (Hallett et al., 2006). This is accomplished by receptor-
receptor interaction, or by striatal-enriched phosphatase, a target of PKA which activates 
the mobilization of glutamate receptor containing vesicles (Braithwaite et al., 2006). In 
contrast, the effect of dopamine D2-like receptors on the postsynaptic site decreases 
glutamate release (Bamford et al., 2004) 
2.8 Basal ganglia 
The organization of the grey matter in the superficial portion of the brain gives 
rise to the cortex while in the deep portion is composed of ganglia. These groups of cells 
are part of the striatum, the thalamus and the mesencephalic ganglia in the cerebrum. The 
striatum is an important input of cortical signal to the basal ganglia while the thalamus 
provides input to the cortex and striatum; additionally, the thalamus brings sensory input 
from the periphery (Bolam et al., 2000). Mesencephalic nuclei provide neuromodulatory 
input to the cortex, striatum and thalamus regulating their function according to other 
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organic functions managed in the brain stem like cardiac, respiratory function as well as 
sleep cycle, eating and the transduction of cranial nerves information. Neurons in the 
basal ganglia use multiple neurotransmitters to transmit and modulate the signal of the 
circuit related to the structures they connect.  
2.8.1 Striatal circuits 
There have been three main striatal pathways described in the literature: The 
excitatory signal from cortical regions synapses at the caudate nucleus, which may 
project through GABAergic medium spiny neurons to the globus pallidus internal 
segment in the direct pathway, or through the globus pallidus external segment in the 
indirect pathway. This latter pathway inhibits the subthalamic nucleus that in turn excites 
the globus pallidus; the third one, a more direct pathway projects from the associative 
cortex directly to the subthalamic nucleus (Nambu et al., 2002). As a consequence, all the 
output from the striatum to the thalamus integrates in the globus pallidus (Nambu, 2007). 
This afferent projections from the globus pallidus will inhibit the relay nuclei of the 
thalamus, which receives them preserving the rostrocaudal topology from the cortex and 
striatum (Kelly and Strick, 2004). The circuit continues with the excitatory thalamo-
cortical projections onto the primary cortex, which closes the loop when inter-cortical 
connections feedback the associative cortices. In accordance with these circuitries, we 
hypothesize that the caudal portion of the caudate nucleus could collect projections from 
associative auditory areas forming an auditory cortico-striatal-thalamo-cortical loop. 
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Figure 1. Diagram of the main brain regions related to the auditory cortico-striato-
thalamo-cortical circuit. Blue arrows depict GABAergic projections. Red arrows show 
glutamatergic projections. Green arrow shows dopaminergic projections. Grey arrows 
correspond to the sensory pathway. 
The striatal cytoarchitecture involves the striosome and the matrix compartments. The 
striosome contains SPNs receive input from the limbic cortex and project to the 
substantia nigra. The matrix receives input from the cortex and projects to the thalamus 
through the striatal pathways processing  somatosensory and associative signal 
(Crittenden and Graybiel, 2011).  
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Abnormal activation of the auditory cortex could arise from an alteration of the striatal 
pathways, which modulate the signal from primary cortices hence generating a 
discrepancy in the recurrent cortico efferent feedback (Kelly and Strick, 2004, Happel et 
al., 2014). The circuits of the basal ganglia regulate neurotransmission of signal from the 
primary cortices to associative cortices, and so information is computed in order to tune 
cortical activity at different levels of the striatum (Graybiel, 1997).  
Dopaminergic projections modulate the striatal pathways, a useful process that helps us 
interpret dysconnectivity among circuits as a pathophysiological mechanism that 
generates schizophrenia-like symptoms (Stephan et al., 2009). These SPNs projections 
synapse neurons in the interface nuclei via two canonical pathways: (a) an indirect 
pathway that first synapse at the globus pallidus external segment and then loops through 
the subthalamic nucleus, and (b) a direct pathway that synapses primarily with the 
interface nuclei constituted by the globus pallidus internal segment and the substantia 
nigra pars reticulata (Nambu, 2007).  
SPNs of the indirect pathway predominantly express D2R while SPNs of the direct 
pathway express D1R (Gerfen et al., 1990, Gong et al., 2003). Consequently, DA release 
in the striatum decreases the output from the interface nuclei to the thalamus by favoring 
a down state in the D2R expressing SPNs of the indirect pathway, or alternatively 
increases the output from globus pallidus by activating D1R expressing SPNs firing in 
the direct pathway (Gerfen and Surmeier, 2011a). The GABAergic projections of the 
globus pallidus in turn disinhibit thalamic activity and allow the glutamatergic thalamic 
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output to the cortex and striatum to increase providing positive feedback to the cortico-
striato-thalamo-cortical circuits (Figure 1). 
The striatal circuits have been mapped with viral vectors showing the topography 
preserved through the pathways (Kelly and Strick, 2004). The head of the caudate 
receives connection from the frontal cortex and motor cortex, while more ventral areas 
connect with the limbic system. In this way, the posterior and narrow portion of the 
striatum has afferent connections from the parietal and sensory cortices (Kimura et al., 
2004). In these neuroanatomical studies, the circuits that interact with the cortex have 
shown close and open loops (Kelly and Strick, 2004). These refer to connection that can 
provide feedback to their cortical origin or that provide input to a different cortical 
region.  
In the case of the motor system, for example, the striatal pathways promote movement 
through the direct pathway or inhibit movement through the indirect pathway (Bateup et 
al., 2010). Interconnections between the striatal pathways provide fine modulation of 
these circuits to select the appropriate the motor pattern. However, the sophisticated role 
of the striatal pathways in filtering and tuning the cortical function requires both direct 
and indirect interaction of circuits (Calabresi et al., 2014). 
2.9 Mechanism for intrinsic auditory activation 
The cells in the striatal pathways work as autonomous pacemakers, which fire 
spontaneously following fluctuations in the resting membrane potential. This activity can 
be modulated by neurotransmitters like dopamine. Recurrent efferent cortical projections 
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provide a feed forward mechanism that may activate cortical networks (Happel et al., 
2014) especially when considering the pacemaker characteristics of the striatal neurons. 
 Corticostriatal inputs has been characterized into two groups: the inter-telencephalic tract 
and the pyramidal tract (Shepherd, 2013). These projections preserve their topography on 
their target regions; hence, they differ in their connectivity to the striosome and matrix 
(Crittenden and Graybiel, 2011). These spiny projecting cells receive an efferent copy of 
cortical activity and primarily synapse in D2R expressing cells (Lei et al., 2004).  Thus, 
imbalances in recurrent circuits with positive feedback onto cortical activity may produce 
intrinsic activation of cortex through striatal networks.  
The effects of dopamine in postsynaptic D2-like receptors on corticostriatal circuits may 
produce enhance cortical auditory activity. A supersensitive D2-like receptor would 
silence the activity of spiny projecting neurons, which in the indirect striatal pathway 
disinhibit GABAergic release by the globus pallidus into the thalamus; therefore, it 
would produce increased output in thalamo-cortical projections.  
The posterior portion of the caudatoputamen receives projections from the auditory 
cortex (Kimura et al., 2004). Due to the preserved anatomical topography of these 
cortical efferent projections throughout their circuits, these subcortical targets project 
back to cortical regions with parallel function; in this case, the posterior caudatoputamen 
would project back to the auditory and parietal cortices. As a result, were the mechanism 
of cortical activation by supersensitive D2-like receptor present in the posterior 
caudatoputamen, it might give rise to enhance auditory activation. 
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CHAPTER 3 
DOPAMINE-INDUCED AUDITORY CORTICAL ACTIVATION AND 
ATTENUATION BY D2-LIKE RECEPTOR-SELECTIVE ANTAGONIST IN THE 
CAUDATOPUTAMEN OF THE RAT 
3.1 Project Summary 
Background: The metabolism of auditory cortex increases during auditory 
hallucinations. These phenomena are a characteristic symptom of schizophrenia. 
Dopamine D2-like receptor antagonists are used to treat schizophrenia, and 
neuromodulatory effects of dopamine in the basal ganglia are central to the 
neuropathology of schizophrenia. However, the mechanisms by which DA dysfunction 
produces symptoms of schizophrenia are not understood.  
Methods: We evaluated the effect of unilateral DA infusion (0, 12.5, 25 and 50 nM in 0.5 
μl saline vehicle), or DA co-infusion with 20 nM eticlopride, a dopamine D2-like receptor 
selective antagonist, into caudal caudatoputamen (-1.8 mm from bregma) on functional 
activity in auditory cortex of rats. Expression of the immediate early gene, zif268 mRNA 
was quantified using in situ hybridization histochemistry as a measure of functional 
activation. The effects of sound (15 dB over ambient) and light exposure on zif268 
mRNA were also examined. 
Results: Striatal dopamine infusion caused a dose-dependent increase of zif268 mRNA 
expression in the auditory cortex, with 50 μM dopamine producing zif268 mRNA 
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expression similar to that produced by sound. These cortical effects were highly localized 
with a distinct laminar pattern. Eticlopride co-infusion attenuated the functional 
activation induced by 50 μM dopamine alone. 
Conclusion: These data are consistent with participation of striatal dopamine in the 
activation of auditory cortex. The regional and laminar localization of this effect suggests 
that perception of sound may be present. The attenuation achieved by dopamine D2-like 
receptor antagonism is consistent with the therapeutic effect of antipsychotics. We 
propose this paradigm as a model of endogenous auditory activation that may elucidate 
the biological bases of psychotic symptoms.  
3.2 Introduction 
Total costs related to schizophrenia are estimated to be $65 billion per year in the 
U.S. alone (Davies and Drummond, 1994, Knapp et al., 2004). With a prevalence of one 
percent and an onset in early adulthood, the occurance of this disease has life-long 
repercussions and a poor prognosis (E, 1971, Freedman, 2003). Perturbations of mental 
functions such as flattened affect, anhedonia and impoverished speech contrast with 
symptoms such as hallucinations and delusions within the clinical framework of 
schizophrenia (Tandon et al., 2013). These manifestations suggest an imbalance of 
multiple circuits and the involvement of various brain regions (Stephan et al., 2009). A 
cardinal symptom characterizing schizophrenia is auditory hallucinations (Battle, 2013), 
wherein increased metabolic activity of the temporal cortex arises from aberrant 
activation (Bentaleb et al., 2002). Excessive dopamine (DA) has been detected in the 
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striatum of patients with schizophrenia(Abi-Dargham et al., 1998), and the affinity of 
antipsychotic drugs for D2-like DA receptors (D2R) correlates with their ability to 
alleviate positive symptoms, including auditory hallucinations (Seeman and Guan, 2008, 
Johnsen et al., 2013, Madras, 2013). In fact, neurons of auditory association cortex in the 
rat project directly to a posterior region of the caudatoputamen (Gangarossa et al., 2013). 
However, much less is known about the putative neuronal mechanisms that link striatal 
DA transmission to activation of the auditory cortex.  
Auditory stimuli normally achieve cortical awareness after relay with neurons in the 
medial geniculate nucleus of the thalamus, whose projections terminate in layer IV of 
primary auditory cortex. The present study evaluated the effect of tonal stimulus 15 dB 
above ambient level on functional activation in the various cortical layers of regions 
within and surrounding auditory cortex. The effect of the tonal stimulus was compared to 
that produced by a DA injection into the region of the posterior caudatoputamen that is 
innervated by auditory association cortex (Kimura et al.), as well as that produced by a 
light stimulus. We also evaluated the effect of a selective D2R antagonist co-infused with 
DA on the functional activity of the auditory cortex. Functional activation was measured 
by expression of the immediate early gene, zif268, which is rapidly affected by natural 
synaptic activity, particularly in cerebral cortex (Worley et al., 1991). This functional 
marker is constitutively expressed, which allows us to assess bidirectional changes in 
neuronal activity.  
We hypothesize that enhanced DA signaling in the posterior caudatoputamen induces 
selective functional activation of auditory cortex in a manner similar to that produced by 
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sound, and that this cortical activation will be blocked by a D2R antagonist; if so, this 
could demonstrate an endogenous brain mechanism to activate the primary auditory 
cortex. We believe these findings are important to better understand the pathophysiology 
of schizophrenia-like symptoms.  
3.3 Experimental Design 
Subjects: Eighty-one adult male Sprague Dawley rats weighing 250 g from 
Charles River Laboratories were group-housed in a temperature- and humidity-controlled 
room, and were habituated to a reverse light/dark cycle (lights on from 1900 to 0900 h) 
for 5 days with food and water available ad lib. All experiments were approved by the 
University of Arizona and Arizona State University Institutional Animal Care and Use 
Committee in accordance to the Guide for the Care and Use of Laboratory Animals.  
Drugs: Dopamine HCl (Patterson Veterinary Supply; Phoenix, AZ) was diluted with 
0.9% sterile saline vehicle to 12.5, 25, 50 and 100 nM solutions. Eticlopride HCl (Tocris 
Bioscience; Minneapolis, MN) was reconstituted with 0.9% sterile saline vehicle to 40 
nM, then infused with an equal volume of 100 nM DA for final concentrations of 50 nM 
DA and 20 nM eticlopride.  
Cannula implantation: Rats were anesthetized with isoflurane and were mounted in a 
stereotaxic frame. Unilateral infusion cannulas targeting the posterior caudatoputamen 
(AP: -1.8 mm, ML: -4.5 mm, and DV: 6.0 mm; Paxinos and Watson, 2007) were 
surgically implanted and fixed to the skull. Rats were then allowed to recover for seven 
days. 
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3.3.1 Striatal dopamine dose dependent study 
We conducted this study with nine rats per treatment group. Rats were randomly 
assigned to one of five treatment groups, which received intracranial infusion of either 
saline vehicle or 12.5, 25 or 50 nM DA with 70 dB ambient sound in a dark chamber, or 
saline vehicle with 85 dB sound in a dark chamber.  
3.3.2 Laminar assessment of the auditory cortex 
In this study, we replicate some of the previous treatments and add a light stimulus to 
assess the specificity of the effect in the auditory cortex. Thus, nine animals per group 
were randomly assigned to four treatment groups.  Three groups received an intracranial 
infusion of saline vehicle and one group 50 nM of dopamine. In the saline vehicle groups 
one received a sound stimulus of 85 dB while the rest had an ambient noise of 70 dB, and 
another group had the light on while the rest had a dark chamber.  
3.3.3 Co-infusion of dopamine antagonists and dopamine in the striatum 
In the following study, four additional groups were randomly assigned to receive 
infusion of saline vehicle, 50 nM DA, 20 nM eticlopride, or 50 nM DA/20 nM eticlopride 
co-infusion, each with 70 dB ambient sound.  
Intracranial infusions (volume: 0.50 μl; infusion rate: 0.25 μl/min; infusion cannula 
remained in place for 5 min, then was slowly withdrawn) were performed, then rats were 
transferred to a sound-attenuated chamber (10” W X 8” D X 10” H) for one hour with the 
appropriate sound level. Immediately following the sound session, rats were anesthetized 
  35 
and perfused with ice-cold 4% buffered paraformaldehyde, and brains were removed, 
post-fixed placed in graded sucrose solutions for 48 h, then stored at -80°C prior to 
processing.  
3.3.4 Zif268 probe labeling 
An oligodeoxyribonucleotide probe whose sequence is complementary to amino 
acids 2-16 of the Zif268 protein 
(5’CCGTTGCTGAGCATCATCTCCTCCAGTTTGGGGTAGTTGTCC3’) was 3’ end-labeled with 
[
35
S]dATP (PerkinElmer; Waltham, MA) using terminal deoxynucleotidyl transferase 
(New England Biolabs; Ipswich, MA), as described previously (Hammer and Cooke, 
1996).  This probe has been characterized by the research group in Graybiel´s laboratory 
where the sense and missense probe were tested for control expression and equivalent 
standards obtained for the quantification of mCi/mg of tissue (Moratalla et al., 1992).  
The implementation of zif268 in the study of dopamine induced metabolic changes in 
brain slices have been previously reported (Keefe and Gerfen, 1996). Briefly, the probe 
was purified and diluted with hybridization buffer containing 50% formamide, 500 µg/ml 
sheared salmon sperm DNA, 250 µg/ml yeast tRNA, 4 × saline-sodium citrate (SSC), 1 × 
Denhardt’s solution, and 10% dextran sulfate/dithiothreitol solution to yield a 3 × 107 
dpm/ml of hybridization solution. 
3.3.5 Tissue preparation and in situ hybridization histochemistry (ISHH) 
Brains were cryosectioned at 20 μm and sections were collected at -3.6 mm to -
4.5 mm from bregma (Paxinos and Watson, 2007), and thaw-mounted on microslides. 
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Infusion sites were confirmed, and slides were prepared for ISHH (Covington et al., 
2005). Briefly, slides were postfixed in 10% formaldehyde in 10 mM phosphate buffered 
saline, pH 7.4 (PBS) for 10 min, rinsed and acetylated in 0.25% acetic anhydride in 0.9% 
NaCl/0.1 M triethanolamide, pH 8.0 (TEA) for 10 min, then dehydrated, delipidated, and 
air-dried. Slides were placed into humidified RNAse-free chambers, covered with 
hybridization solution under Parafilm® coverslips overnight at 37°C. Coverslips were 
removed and slides were washed at 23°C in 0.3 M NaCl sodium 30 nM socidium citrate, 
pH 7.0 (2× SSC) and 50% formamide for 1 h, twice in 1× SSC and once in 0.5× SSC for 
30 min each,  then washed in 0.1 SSC at 37 °C for 30 min. The tissue was washed twice 
in 1 × SSC for 30 min, and dehydrated in graded ethanol solutions before being air-dried. 
Hybridized slides were randomized and exposed to Biomax-MR X-ray film (Carestream 
Health) co-exposed with calibrated radiostandards (American Radiolabeled Chemicals; 
St. Louis, MO) which had been cross-calibrated to 
35
S-brain paste standards (Hammer, 
Bogic and Handa, 1993); films were developed using a table-top processor (Konica 
Minolta, SRX-101A).  
3.3.6 Image analysis 
Films were scanned for densitometric analysis using ImageJ analysis software 
(created by Wayne Rasband; available at: http://rsb.info.nih.gov/ij/). Each film had a 
radio standard for calibration of the respective slides. Slides were stained with cresyl 
violet stain and scanned to permit precise localization of brain regions. Thus, the 
agranualar motor cortex was differentiated from the granular auditory and the visual 
cortex. Due to the intersperse distribution of layer IV on the rostrocaudal access 
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distinction of the surrounded secondary sensory cortex was not carried out. Then, high 
resolution scans of autoradiographs and stained sections were aligned using TurboReg 
image registration plug-in (created by Philippe Thévenaz; available at: 
http://bigwww.epfl.ch/thevenaz/turboreg/). Following calibration using autoradiographic 
images of the radiostandards, anatomical regions of interest were outlined on the stained 
section and zif268 mRNA was quantified on film images in terms of mCi/mg tissue 
protein. The depth of each layer was recorded in pixels and the distance then calculated 
as a factor of 2.6 μm per pixel. To facilitate comparisons between layers in our model 
each layer was then consider as a percentage of total cortical depth. In this manner, in the 
auditory cortex Layer II: 11%, Layer III: 12%, Layer IV: 22%, Layer V: 25% and Layer 
VI: 30%. In the motor cortex Layer II: 14%, Layer III: 34%, Layer IV: 0%, Layer V: 
63% and in the visual cortex Layer II: 14%, Layer III: 26%, Layer IV: 47%, Layer V: 
74%. 
3.3.7 Statistical analyses 
ANOVAs were performed to determine treatment effects using the following 
planned comparisons: (a) difference in mean expression of zif268 between ipsilateral and 
contralateral auditory cortices, (b) differences between doses of dopamine, (c) differences 
between cortical layers along rostro-caudal levels of the auditory cortex, (d) differences 
between co-infused eticlopride and all other dopamine groups. (e) differences between 
auditory, motor and visual cortices. Specific effects were evaluated considering 
Bonferroni’s adjustment for multiple comparisons. 
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3.4 Results 
3.4.1 Localization of infusion site 
Our results require a specific accurate target region for all intracranial injections 
in order to produce a precise effect; hence, the injection sites for each intracranial surgery 
were located. Before sectioning the target region, every brain was section through the 
injection site area at -1.8 mm from Bregma. The stereotaxic coordinates were recorded 
and later plotted into a slide of rat brain atlas. Most of the injections were located in an 
area 0.8 mm around the target (Figure 2).There were four injections that turn out in a 
more dorsal position though they were still within the caudatoputamen. Two injections 
were in the borders with the globus pallidus and one in a more dorsal position. 
Nevertheless, all injections were within the target region of the posterior 
caudatoputamen.    
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Figure 2. Target region and injection sites recorded for intracranial injections of 
dopamine doses and saline vehicle.  
3.4.2 Sound and DA dose dependently increase expression of zif268 mRNA in auditory 
cortex 
We quantified the expression of zif268 mRNA across all layers of auditory cortex 
from rats held within a sound attenuated chamber at ambient sound levels of 70 and 85 
dB (Figure 3A). The 85 dB stimulus significantly increased functional activation of the 
entire auditory cortex compared to 70 db ambient sound (∆ = 0.444, t = 4.95, p ≤ 0.0001). 
Therefore, 70 dB sound was utilized as the background sound in all subsequent infusion 
experiments.  
 
Figure 3. Effects of 12.5 nM, 25 nM and 50 nM of DA infusion and 85 dB sound 
stimulus in the caudal caudatoputamen on the expression of zif268 mRNA in auditory 
cortex.   
Figure 3A. Each hemisection corresponds to an example of a treatment group. 
Autoradiography of zif268 mRNA at -4.3 mm from bregma. The delineated area of the 
temporal cortex corresponds to the quantified auditory region.  
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We then examined functional activation of auditory cortex following infusion of 0, 12.5, 
25, or 50 nM doses of DA, and compared the DA effects to those produced by ambient 
sound levels of 70 or 85 dB (Figure 3B & Table 1). Infusion of 12.5 nM of DA 
significantly increased zif268 mRNA expression in the auditory cortex (12.5 nM DA vs. 
vehicle ∆ = 0.187, t = 2.08, p ≤ 0.05). A 25 nM injection of DA produced similar 
expression of zif268 mRNA in the auditory cortex to the 12.5 nM DA injection, and 
significantly higher than vehicle (25 nM DA vs. vehicle ∆ = 0.224, t = 2.50, p ≤ 0.05). 
Subsequently, the increase from 25 nM to 50 nM of DA augmented the expression of 
zif268 mRNA up to an equivalent activation generated by a sound 15 dB higher than 
ambient noise (50 nM DA vs. vehicle ∆ = 0.484, t = 5.69, p < 0.001) (Figure 3B).  
 
Figure 3B. Mean expression of the zif268 mRNA in the auditory cortex after incremental 
doses of DA. There is a dose dependent effect with increased dose of DA (ANOVA 
F(4,24): 10.48, p<0.00001).   
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 Auditory Cortex 
 0.0000 
 Vehicle 85 dB Sound 
85 dB Sound 0.000  
50 nM DA 0.000 0.681 
25 nM DA 0.050 0.037 
12.5 nM DA 0.048 0.042 
 
Table 1. P values of planned comparisons of the zif268 mRNA expression after DA 
injection in the posterior caudate. 
Interestingly, comparison of functional activation between hemispheres revealed no 
significant differences in response to any DA dose (12.5 nM Right vs. Left F(1,8): 0.03, p 
> 0.05; 25 nM Right vs. Left F(1,10): 0.26, p > 0.05; 50 nM Right vs. Left F(1,8): 3.37, p > 
0.05) (Figure  3C). 
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Figure 3C. Inter-hemispheric comparison of zif268 mRNA expression in the auditory 
cortex. No significant differences were detected in the expression of zif268 mRNA when 
comparing the two hemispheres.   
 
Figure 4. Functional activation by sound, dopamine, light and saline treatments in the 
cortical layers of the auditory, visual and motor cortices. Mean zif268 mRNA expression 
shown in the Y axis for every treatment across the cortical regions evaluated. Error bars 
depict one standard error of the mean.  
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Treatments Saline  Sound  Light  Dopamine  
 0.0173  0.0398  0.0237  0.0000  
 Auditory Visual Auditory Visual Auditory Visual Auditory Visual 
Visual 0.924  0.290  0.784  0.002  
Motor 0.481 0.014 1.000 0.046 0.605 0.020 1.000 0.000 
 
Table 2. P-values of ANOVA and Bonferroni’s test hypothesizing equal functional 
activation in auditory, visual and motor regions. 
Note 1: Table reports the p-values of the F-statistic for ANOVA testing the hypothesis of 
equal mean zif268 mRNA expression between brain regions by treatment (top region of 
the table). Planned comparisons using Bonferroni’s adjusted F-statistic were carried out 
subsequently to detect specific regional differences (Bottom region of the table). Refer to 
Annex 2 for details of each test. 
After a comparison of treatment effects between regions, saline treatment showed low 
levels of zif268 mRNA expression in all brain regions. The motor region, however, 
exhibits higher functional activation compared to the auditory and visual regions. This 
was observed in all treatments including saline. Such effect could be explained by 
deambulation of the animals in the sound insulated chamber, though the higher 
constitutive expression levels in the motor cortex may mask its assessment as control 
region for sensory brain areas. Moreover, the light treatment showed unexpected low 
activation of the visual cortex. In fact, the visual region showed the lowest functional 
activation in all treatments. The effects of sound and dopamine treatments did replicated 
our previous findings inducing higher functional activation, especially in the auditory and 
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motor regions. These mean expression levels were followed up with post-hoc testing to 
identify differences between cortical layers.  
Saline Layer II Layer III Layer IV Layer V Layer VI 
 0.0941 0.2370 0.5653 0.0805 0.0522 
 Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Auditory 7 70 7 71 7 57 7 75 6 73 
Visual 7 56 7 61 7 48 7 52 6 51 
Motor 7 105 7 99 .  7 104 5 107 
  
Sound Layer II Layer III Layer IV Layer V Layer VI 
 0.0813 0.3102 0.2002 0.3551 0.8712 
 Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Auditory 7 62 6 60 6 47 6 54 6 59 
Visual 7 32 6 39 6 31 6 42 6 50 
Motor 7 58 5 54 . . 5 57 5 44 
 
Light Layer II Layer III Layer IV Layer V Layer VI 
 0.0444 0.1837 0.3865 0.1532 0.4152 
 Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Auditory 9 122 9 128 9 90 9 118 9 116 
Visual 8 65 8 73 8 63 8 75 8 85 
Motor 8 138 8 124 . . 8 132 8 124 
 
Dopamine Layer II Layer III Layer IV Layer V Layer VI 
 0.0157 0.0075 0.0283 0.0240 0.0455 
 Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Obs 
Rank 
Sum 
Auditory 5 51 5 48 5 38 5 44 5 47 
Visual 5 25 5 15 5 17 5 19 5 20 
Motor 5 60 5 57 . . 5 57 5 53 
 
Table 3. P-values of Kruskal-Wallis test hypothesizing similar functional activation in 
brain regions by cortical layers 
Note 1: Cortical Layer II (Cortical depth ≤ 11%), Layer III (11% < depth ≥ 23%), Layer 
IV(23% < depth ≥ 45%), Layer V(45% < depth ≥70%), Layer VI(70% < depth ≥ 100). 
Saline: control treatment to Sound, Light and Dopamine. Light: control modality 
treatment to Sound. Dopamine: hypothesis treatment. Motor (-3.8 mm from bregma): 
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Control brain region to Auditory and Visual. Visual (-5.8 mm from bregma): Control 
modality region to Auditory. 
Note 2: Tables report the p-values of the Kruskal-Wallis test hypothesizing equal zif268 
mRNA expression between brain regions at each cortical layer (Top region of each table). 
The number of brains per region is listed under the column Obs. The rank of the region 
within each layer per treatment is listed under Rank Sum. Refer to Annex 2 for detail of 
each test.   
At the laminar level, each brain region has a distinctive cytoarchitecture. The most 
predominant factor is the well-differentiated layer IV in sensory cortices, which is almost 
absent in the motor cortex. Therefore, a non-parametric analysis allowed between regions 
laminar comparisons without violating the normality and equal variances assumptions for 
ANOVA. A Kruskal-Wallis test was performed to test if the zif268 mRNA expression 
was similar between auditory, visual and motor regions at each cortical layer. 
Dopamine treatment induced a higher expression of zif268 mRNA in all layers of the 
motor cortex compared to the sensory regions. In the sensory regions, dopamine induced 
higher functional activation in layer IV of the auditory cortex compared to the same layer 
in the visual cortex. This effect in the input layer of sensory regions was not statistically 
differentiable in sound or light treatment groups. Other treatments did not report 
significant laminar differences between regions, except for the layer II after light 
treatment. In spite of the low effect by light in the visual cortex, the predominant effect of 
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dopamine in the auditory cortex indicated that a more detailed evaluation of within each 
brain region was necessary. 
Laminar analysis: The response in each layer of auditory cortex to 50 nM striatal DA 
infusion was then compared across rostro-caudal levels from bregma -3.8 mm to -5.2 mm 
(Paxinos and Watson, 2007) (Figure 5), which revealed a significant main effect of level 
(F(4,24): 10.48, p ≤ 0.00001). Dopamine-induced functional activation was greater -4.4 
mm from bregma (ANOVA: level -4.4 mm F(3,23): 4.06, p ≤ 0.05). Dopamine showed a 
lesser effect on zif268 mRNA expression at -4.0 mm level with intermediate readings at -
3.8 mm and -4.2 mm levels. By contrast, striatal DA infusion had no effect on zif268 
mRNA expression in agranualar motor cortex (F(4,38): 0.75, p > 0.05). Laminar analysis of 
cortex conducted across the same rostro-caudal levels revealed that 85 dB sound 
significantly increased zif268 mRNA expression in layers III and IV at -3.8 mm, and in 
all layers at --4.0, -4.8 and -5.2 mm from bregma compared to the saline group (Table 2). 
Even though the effect of light treatment can be statistically differentiated from sound 
treatment in layers II-IV at -4.0 mm from bregma, light treatment was not statistically 
significant different from control group in any other rostrocaudal level. 
  47 
 
Figure 5. Functional activation of the auditory cortex by sound, dopamine, light and 
saline treatments in cortical layers at six rostrocaudal levels. Mean expression of zif268 
mRNA from -3.8 mm to -5.2 mm levels of the temporal cortex across cortical depth for 
each treatment group.  
Black: Saline intracranial injection (Control group); Blue: 85 dB sound stimulus group 
(Modality specific treatment); Green: Light group (Modality control treatment); Red: 
Dopamine group (Modality hypothesis treatment). Error bars depict one standard error 
around the mean. Plus signs on top of error bars depict significant difference between 
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treatments within a cortical layer. On the rostrocaudal axis, each level has a different 
input profile: At -3.8 mm from bregma all treatment groups differ in the expression level 
of zif268 mRNA with sound producing a higher effect. At -4.0 mm from bregma, sound 
treatment generates activation while other treatments show low activation levels. The 
posterior levels (-4.2 mm and -4.4 mm) do not exhibit sound induced activation while 
dopamine treatment activates the auditory cortex at -4.4 mm and other treatments show 
low zif268 mRNA expression. 
-3.8 mm Layer II Layer III Layer IV Layer V Layer VI 
 0.0704 0.0312 0.0576 0.0666 0.0376 
 Saline Sound Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.088  0.032  0.054  0.066  0.041  
Light 1.000 0.318 1.000 0.176 1.000 0.263 1.000 0.295 1.000 0.207 
Dopamine 0.682 1.000 0.510 1.000 1.000 1.000 1.000 1.000 0.513 1.000 
 
-4.0 mm Layer II Layer III Layer IV Layer V Layer VI 
 0.0029 0.0086 0.0077 0.0224 0.0285 
 Saline Sound Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.002  0.008  0.007  0.019  0.024  
Light 1.000 0.021 1.000 0.031 1.000 0.033 1.000 0.100 1.000 0.154 
Dopamine 0.292 0.537 1.000 0.226 1.000 0.176 1.000 0.643 0.877 0.909 
 
-4.2 mm Layer II Layer III Layer IV Layer V Layer VI 
 0.0931 0.0463 0.0860 0.0573 0.0727 
 Saline Sound Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.119  0.091  0.146  0.089  0.103  
Light 1.000 0.449 1.000 0.257 1.000 0.357 1.000 0.391 1.000 0.534 
Dopamine 0.703 1.000 0.314 1.000 0.597 1.000 0.339 1.000 0.388 1.000 
 
 
-4.4 mm Layer II Layer III Layer IV Layer V Layer VI 
 0.0138 0.0259 0.0291 0.0146 0.0211 
 Saline Sound Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.276  0.189  0.459  0.298  0.627  
Light 1.000 0.826 0.986 1.000 1.000 1.000 0.814 1.000 1.000 1.000 
Dopamine 0.020 1.000 0.028 1.000 0.027 1.000 0.011 0.865 0.018 0.680 
 
-4.8 mm Layer II Layer III Layer IV Layer V Layer VI 
 0.0867 0.0081 0.0010 0.0013 0.0025 
 Saline Sound Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.094  0.009  0.001  0.001  0.002  
Light 1.000 0.969 0.264 0.642 0.017 0.750 0.018 0.892 0.019 1.000 
Dopamine 1.000 0.357 1.000 0.059 0.272 0.214 0.300 0.242 0.245 0.550 
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-5.8 mm Layer II Layer III Layer IV Layer V Layer VI 
 0.2447 0.0124 0.0377 0.0033 0.0079 
 Saline Sound Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.424  0.039  0.053  0.002  0.005  
Light 0.978 1.000 0.122 1.000 0.176 1.000 0.180 0.266 0.314 0.327 
Dopamine 1.000 1.000 1.000 0.087 1.000 0.504 1.000 0.091 1.000 0.211 
Table 4. P values of MANOVA and Bonferroni’s adjusted F-statistic hypothesizing 
similar functional activation in layers of the temporal cortex by treatments at each 
rostrocaudal level.  
Note 1: Cortical Layer II (Cortical depth ≤ 11%), Layer III (11% < depth ≥ 23%), Layer 
IV(23% < depth ≥ 45%), Layer V(45% < depth ≥70%), Layer VI(70% < depth ≥ 100). 
Saline: control treatment to Sound, Light, and Dopamine. Light: control modality 
treatment to Sound. Dopamine: hypothesis treatment. 
Note 2: Tables report the p-values of the F-statistic for MANOVA testing the hypothesis 
of equal mean zif268 mRNA expression between treatment groups at each rostrocaudal 
level (top panel on each table). Planned comparisons using Bonferroni’s adjusted F-
statistic were carried out subsequently to detect specific treatment effects per layer 
(bottom panel on each table). Highlighted values depict statistical significance achieved. 
Refer to Appendix 2 for details on each test. 
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-3.6 mm Layer II Layer III Layer V Layer VI 
 0.2726 0.2578 0.3613 0.4271 
 Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.535  0.002  1.000  1.000  
Light 1.000 1.000 0.180 0.266 1.000 1.000 1.000 1.000 
Dopamine 0.681 1.000 1.000 0.091 0.719 1.000 0.771 1.000 
 
 
-3.8 mm Layer II Layer III Layer V Layer VI 
 0.0423 0.0453 0.0759 0.1742 
 Saline Sound Saline Sound Saline Sound Saline Sound 
Sound 0.038  0.044  0.088  0.256  
Light 1.000 0.290 1.000 0.487 1.000 0.600 1.000 1.000 
Dopamine 0.599 1.000 0.396 1.000 0.484 1.000 0.665 1.000 
 
Table 5. P-values of MANOVA and Bonferroni’s adjusted F-statistic hypothesizing 
similar functional activation in layers of the motor cortex by treatments at each 
rostrocaudal level.  
Note 1: Cortical Layer II (Cortical depth ≤ 11%), Layer III (11% < depth ≥ 23%), Layer 
IV(23% < depth ≥ 45%), Layer V(45% < depth ≥70%), Layer VI(70% < depth ≥ 100). 
Saline: control treatment to Sound, Light and Dopamine. Light: control modality 
treatment to Sound. Dopamine: hypothesis treatment. 
Note 2: Tables report the p-values of the F-statistic for MANOVA testing the hypothesis 
of equal mean zif268 mRNA expression between treatment groups at each rostrocaudal 
level (top region on each table). Planned comparisons using Bonferroni’s adjusted F-
statistic were carried out subsequently to detect specific treatment effects per layer 
(Bottom region on each table). Refer to Annex 4 for details of each test. 
The effects of sound were significantly greater in layers II and III at -3.8 mm from 
bregma. Dopamine and sound treatments induced a mean expression of zif268 mRNA up 
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to 0.35 mCi/mg in level -3.6 mm. Although there were no differences between the effects 
of other treatments, it is important to mention that all treatments including saline showed 
higher functional activation. 
3.4.3 Dopamine selective antagonist attenuate dopamine induce auditory activation 
Eticlopride was co-infused with DA in order to avoid non-specific effects of D2R 
blockade in other brain regions. Compared to infusion of DA alone, co-infusion in the 
posterior caudatoputamen significantly reduced expression of zif268 mRNA in auditory 
cortex  (F(1,39): 8.836, p ≤ 0.005), to a level that did not differ from that produced by 
infusion of vehicle (Fig. 3). Eticlopride alone did not alter zif268 mRNA expression in 
auditory cortex compared to vehicle treatment (F(1,39): 1.084, p = 0.305), nor did co-
infusion or eticlopride infusion affect functional activation in agranular motor cortex (F(5, 
39): 0.609, p = 0.69).  
 
Figure 6. D2-like selective antagonist attenuates DA-induced functional activation of 
auditory cortex. 
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Figure 6A. Each hemisection corresponds to an example from each treatment group. 
Autoradiography of zif268 mRNA at the auditory cortex.  
 
Figure 6B. Mean expression of zif268 mRNA in auditory cortex after injection of 50 nM 
of DA, 20 nM of eticlopride or coinfusion of 50 nM of DA + 20 nM of eticlopride. * 
indicates statistically significant comparisons.  DA: 50 nM DA increased zif268 mRNA 
expression in auditory cortex (Saline vs. DA F(1,39): 19.139, p ≤ 0.001). Eticlopride alone 
did not alter zif268 mRNA expression (Saline vs. eticlopride, F(1,39): 1.084, p = 0.305).  
Co-infusion of DA and eticlopride decreases the expression of zif268 mRNA produced by 
DA alone (DA vs. DA-eticlopride, F(1,39): 8.836, p = 0.005). This expression level was 
not statistically differentiable from Vehicle treatment. 
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3.5 Discussion 
  The unilateral infusion of incremental doses of DA in the caudal caudatoputamen 
produces a dose-dependent increase in the expression of zif268 mRNA in the posterior 
auditory cortex, which confirms that this portion of the striatum is selectively associated 
with the auditory cortex. This finding is consistent with the participation of the 
caudatoputamen in processing of the auditory modality (LeDoux et al., 1991). 50 nM DA 
unilateral injection reproduced the functional activation generated by a sound stimulus of 
85 dB.  
The effect of DA was also observed in the contralateral auditory cortex, which suggests 
close communication between the temporal cortices of both hemispheres through trans-
callosal cortico-cortical projections (Shepherd, 2013). Importantly, the auditory cortex 
appears to be selectively activated at -4.4 mm from bregma by an injection of DA in the 
caudate at -1.8 mm from bregma. This effect denotes a preserved topology in the striato-
thalamo-cortical circuit. The precise increase of the expression of zif268 mRNA in rostro-
caudal axis suggests that the effect of DA from the posterior caudate has specific circuits 
that project into a rostro-caudal level of the auditory cortex.  
The functional activation of the temporal cortex affects all cortical layers demonstrating 
network connectivity within cortical columns. Across the cortical depth, a higher 
activation level was seen in the input layers, which characterizes this portion of the 
temporal cortex as a sensory brain region with a predominant input component. 
Therefore, in order to functionally demonstrate that this temporal brain region is auditory, 
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we carried out a laminar analysis after sound or light stimuli. The effects of sound 
stimulus increased zif268 mRNA expression in layer III-IV throughout the temporal 
segment (-3.8 mm to -5.2 mm from bregma) of the cortex, revealing the auditory sensory 
input of this brain region.  
A sound stimulus of 85 dB was able to produce bilateral functional activation of the 
auditory cortex similar to one caused by DA infusions in the caudatoputamen. A light 
stimulus did not induce activation significantly higher than the vehicle treatment at any 
rostro-caudal level. There was no activation in agranualar motor cortex after DA infusion 
in the caudal striatum, suggesting that this portion of the caudal caudatoputamen is more 
strictly related to auditory rather than motor processing. These findings suggest that the 
portions covered by our DA manipulations are specifically related to auditory input. 
D2R selective antagonist attenuated the effect of striatal DA infusion on functional 
activation of auditory cortex. The co-infusion of eticlopride, a selective D2R antagonist 
lowered the expression of zif268 mRNA to control group levels. D2R antagonist may 
affect presynaptic DA and glutamate release, as well as, postsynaptic firing of D2R 
expressing SPNs. Under this assumption, the attenuation produced by eticlopride may 
take place via postsynaptic D2R by setting SPNs of the indirect pathway in a down 
functional state, which in turn decreases thalamo-cortical output, rather than through 
presynaptic D2R, which increases dopaminergic and glutamatergic release, and 
subsequently increases thalamo-cortical output. Such D2R antagonist effect is consistent 
with clinical improvement produced by antipsychotics, which are found to be correlated 
with their D2R affinity (Madras, 2013).     
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The pharmacological manipulations advanced in this study presents evidence for the 
involvement of striatal DA transmission in activation of the auditory cortex. Given that 
similar activation of rat auditory cortex is produced by sound, the present analyses 
suggest that dopamine affects both direct- and indirect-pathway SPNs that in turn provide 
intrinsic auditory stimulation. These findings suggest the presence of an auditory striato-
pallido-thalamo-cortical circuit, whereby supersensitive postsynaptic D2R signaling in 
the caudal caudatoputamen induces bilateral activation of the auditory cortex.  
We propose this paradigm as a model of endogenous auditory stimulation that may 
elucidate the biological basis of psychotic symptoms, such as auditory hallucinations. 
Further study of the projections within this striato-auditory cortical loop is required to 
describe the nature of this functional relationship. Likewise, a dose-response study is 
needed to better describe the effects of selective DA antagonists in this paradigm.  
Our results characterized the molecular mechanisms of the affected circuit responsible for 
auditory endogenous activation and provide a strong neurobiological foundation to 
understanding auditory dysfunction. This model will also facilitate the study of abnormal 
cortical cadence that resembles schizophrenia like symptoms, thus aligning to the 
objectives of the National Institutes of Mental Health. 
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CHAPTER 4 
TRANS-SYNAPTIC RETROGRADE TRACING OF AN AUDITORY CORTICAL 
CIRCUIT FROM THE POSTERIOR CAUDATOPUTAMEN 
4.1 Project summary 
Background: Functional studies have reported activation of the auditory cortex 
during verbal auditory hallucinations, as well as increased dopamine transmission in the 
caudatoputamen. We have shown that dopamine infusion into the posterior 
caudatoputamen of the rat dose-dependently activates auditory cortex, as does a sound 
stimulus, and that co-infusion of a selective D2-like antagonist attenuates this effect. 
Hence, this work seeks to describe the neuronal connectivity from the posterior 
caudatoputamen to the auditory cortex through a cortico-striato-thalamo-cortical (CSTC) 
pathway.  
Methods: The circuit was assessed using a retrograde trans-synaptic tracer.  We infused 
PRV-152 in layer IV of the Au of 21 rats. The progression of the infection was evaluated 
every 12 h post-inoculation. The sensory and striatal pathways were evaluated by 
chronologically mapping the location of eGFP-expressing neurons and synaptic level of 
the projections estimated using viral kinetics.  
Results: Our results reveal neuronal pathways that connect the auditory cortex and 
caudatoputamen. We identified direct thalamic projections to auditory cortex from the 
medial geniculate and the ventral anterior – ventral lateral nuclei. These thalamic 
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projections depict different rostrocaudal input sources to auditory cortex. Indirect 
projections to auditory cortex were also identified from ipsilateral posterior 
caudatoputamen, subthalamic nuclei, and globus pallidus. 
Discussion: These neuroanatomical data delineate a neural circuit, which may underlie 
striatal dopamine-induced functional activation of auditory cortex. We demonstrate here 
that the posterior caudatoputamen innervates the auditory cortex through a CSTC 
pathway. We propose that this auditory CSTC pathway represents a biological substrate 
for intrinsic activation of the auditory cortex, and may be important in the 
pathophysiology of verbal auditory hallucinations. 
4.2 Introduction 
The perception of sound is directly associated with the activation of the temporal 
cortex (Lennox et al., 2000). Normally, an auditory stimulus is transduced into neuronal 
signals and carried by the sensory auditory pathway from the inner ear to the auditory 
cortex; however, auditory perception may appear without sound stimulation, causing the 
human brain to generate and intrinsic perception of sound. (Grassian, 1983).  An example 
of this phenomena is auditory hallucinations, which is characteristic of some psychotic 
disorders, including schizophrenia. (Allen et al., 2008, Kronmuller et al., 2011). Research 
on psychotic syndrome has shown an aberrant dopaminergic transmission (Abi-Dargham 
et al., 1998), more specifically, a hypersensitive dopamine D2-like postsynaptic receptor 
component that interferes with the modulation of corticostriatal and thalamostriatal 
projections (Bonci and Hopf, 2005, Surmeier et al., 2007, Madras, 2013).  
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Based on this knowledge, dopamine antagonists have remained the first line of treatment 
for symptoms of psychotic disorders, including verbal auditory hallucinations  (Buchanan 
et al., 2002, Lieberman et al., 2005). In addition, animal models for the schizophrenia 
spectrum of symptoms have revealed that increased dopamine transmission in the 
posterior caudatoputamen induces activation of the auditory cortex, and that selective D2-
like receptor antagonists attenuates this effect (A. Parga, 2012).  Consequently, a 
dopaminergic imbalance in the striatum may generate the intrinsic activation of the 
auditory cortex in the psychotic brain.  
The present study seeks to describe the neuronal circuit that affects the auditory cortex 
after dopamine manipulations in the posterior caudatoputamen. Previous studies reported 
functional connectivity between the auditory cortex and the striatum (Hoffman et al., 
2011). Nonetheless, the pathway by which the auditory cortex is intrinsically activated 
has been elusive, perhaps due to its multisynaptic nature. We hypothesized that the 
posterior caudatoputamen affects the auditory cortex through a striato-thalamo-cortical 
circuit. We based this hypothesis on the topological organization of the striato-thalamo-
cortical loops, which in the posterior aspect of the caudatoputamen project to temporal 
cortex (Kimura et al., 2004).  
4.2.1 Tracing of neuronal circuits 
In order to map the striatal projections to the auditory cortex, a multisynaptic 
tracing technique is necessary; therefore, we implemented the trans-synaptic tracer, 
pseudorabies virus (PRV) 152. PRV strains have been broadly used to describe 
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multisynaptic pathways in the brain due to the selective neurotrophic attribute of these 
viruses (Callaway, 2008, Ugolini, 2010). We used PRV-152 because of  its ability to 
express enhanced green fluorescent protein (eGFP) as an indicator of trans-synaptic 
retrograde infection, as well as its slower transmission and reduced cytopathic effects 
(Banfield et al., 2003, Enquist, 2012). The cycle of viral replication takes approximately 
12 hours before PRV-152 trans-synaptically infects new neurons. This produces a new 
level of neurons at a constant rate per synaptic level, which facilitates the mapping of 
projections.  
We aim to detect the projections involved in the neuronal pathway that impinges on the 
auditory cortex from the caudatoputamen. To discriminate the sequence of viral spread 
through the circuit levels, the sensory auditory pathway will serve as a canon for the viral 
spread in the auditory striatal pathway. In this manner, we expect to retrogradely label 
afferent projections from the ventral posterior and ventral lateral (VA/VL) nuclei as well 
as the medial geniculate nucleus (MGN) in the first level of neurons; subsequently, the 
viral detection in striatal structures will demonstrate that further synaptic levels are 
involved in the striatal input signal to the auditory cortex. 
4.3 Experimental design 
4.3.1 Animals 
Twenty-one adult male Sprague-Dawley rats (250 gm) were group housed in a 
biosafety level 2 (BSL-2) approved facilities, with HEPA filtered animal isolation units. 
Animals were maintained in reverse light cycle (12:12 h, lights on at 0900 hours) with 
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free access to food and water. All experiments were carried out following the guidelines 
of the National Institute of Health Guide for the Care and Use of Laboratory Animals, 
and the protocol approved by the University of Arizona Institutional Animal Care and 
Use Committee.  
4.3.2 Virus 
Pseudorabies virus 152 was obtained from the Center for Neuroanatomy and 
Neurotropic Viruses at University of Pittsburgh. Virus was only handled in biosafety 
cabinet BSL-2. 100 μl aliquots of the neurostock were made in cryovials and after snap-
freeze in dry ice stored at -80 C. Individual vials were thawed before intracerebral 
injections. One aliquot was used to inject up to three animals (100 nl of 7×10
4
 pfu/ml) 
(Card et al., 1999), all excess of virus was inactivated with bleach before being discarded 
into the appropriate biohazard waste. 
4.3.3 Experimental paradigm 
To establish the appropriate time of detection (TOD) of the regions of interest 
(ROI) an initial study was conducted to evaluate the progression of the viral spread 
during 72 hour after viral infusion at twelve hours intervals. For this purpose, six animals 
received intracerebral infusion of PRV-152 (see 4.3.4 intracerebral injections) and one 
animal was assessed at every post-inoculation time (n=1). Once the TOD for the 
caudatoputamen was found, we evaluated a period from 24 to 48 hours after inoculation 
at six hours intervals to detect more precisely the viral spread between the second and 
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fourth synaptic levels.  In this later study fifteen animals (n=3) received the same PRV-
152 injection and three animals were assessed at every post-inoculation time (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Time line of post-inoculation times evaluated. A) Initial exploratory study 12 – 
72 h / 12h. B. complementary study 24 – 48h /6h  to obtain detail on the third synaptic 
rank. 
4.3.4 Intracerebral injections 
After pre-anesthesia evaluation in the vivarium, animals were transported to the 
BSL-2 procedure room. Then, anesthesia was induced with inhaled isoflurane in a 
protection chamber. Animals were placed in a stereotaxic frame and a surgical window 
was opened in the scalp to identify the bregma location. The skull was drilled at target 
coordinates for the right auditory cortex according to rat brain atlas (Ashwell et al., 
2007). A 1 μl Hamilton syringe equipped with 26 gauge cannula was loaded with 0.5 μl 
of neurostock and then connected to the infusion pump. The tip of the cannula was placed 
at the target coordinates (AP -4.3 mm, ML 6.69 mm, DV -4.45 mm) for layer IV of the 
Hours: 0 12 24   36 48 60 72 
n:  1 1 1 1 1 1 
Hours: 0  24    30 36   42 48 
n:   3      3 3     3 3 
PRV-152 
PRV-152 
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secondary auditory cortex, and 100 nl of neurostock were infused at a rate of 10 nl per 
minute. The cannula was removed five minutes post infusion to prevent reflux. The scalp 
incision was sutured with staples and the animals were monitored until fully recovered 
from anesthesia. After recovery, animals were transferred to HEPA filtered animal 
isolation unit. All animals received the analgesic Buprenorphine 0.06 mL and were 
followed up every twelve hours post-surgery.   
4.3.5 Tissue processing 
At the designated post-inoculation time, each animal was euthanized with an 
intraperitoneal injection of 0.06 ml of 39% pentobarbital sodium solution. Then, the brain 
was perfused in situ with a transcardial infusion of 100 ml of 10% heparin solution 
followed by 250 ml of 4% paraformaldehyde, pH: 8.0 at a rate of 25 ml/minute. After the 
brain was removed from the skull, it was prepared for cryosection by post-fixation in 4% 
paraformaldehyde at 4 °C for two hours and overnight immersion in 12.5% and 25% 
phosphate buffer sucrose solution, pH: 7.4 at 4 °C. Each brain was sectioned at 30 
μm/section from -1.0 mm to -8.3 mm from bregma; in this manner, we have a sample of 
each brain every 90 m in the anterior-posterior axis. The location of the injection sites 
was confirmed to be within the temporal cortex and at -4.3 mm from bregma. Sequential 
sections were mounted onto glass slides and coverslipped with ProLong ® Gold antifade 
reagent, which labels the nucleus of cells with 4',6-diamidino-2-phenylindole (DAPI) for 
posterior anatomical characterization. Sections were allowed to cure overnight at 4 C° 
before imaging.  
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4.3.6 Fluorescent imaging 
Each section was imaged at 20X magnification in a Zeiss Axioskope equipped 
with epifluorescent (488 nm) filter, a motorized stage, and MBF CX 9000 color camera. 
Images were stitched into a virtual slide using Neurolucida (MBF-Bioscience, 2012). 
After background correction, images were flattened and the cells expressing eGFP were 
detected and marked using an automatic detection object module set to 86% sensitivity, 
and body size ratio of 40 μm to 450 μm in diameter. Cell markers were confirmed with 
the live DAPI signal at the microscope.  
4.3.7 Analysis of tissue 
The virtual slides were superimposed on the rat brain atlas and a rostrocaudal 
level was assigned to each section. The contours of the section, the thalamus, the 
hippocampus and the caudatoputamen were traced in a template file. These contours and 
the cell markers were classified with different user categories according to the 
hemisphere and the brain region. Then, template files were aligned into an image stack 
using the center of the section contour and the section middle line as landmarks. A 3D 
reconstruction of each brain was rendered from the image stack and used for the 
topographical analysis of the viral spread. Using the 3D reconstruction the stereotaxic 
coordinates were defined for the center of each ROI (Table 3). Then, we recorded cell 
counts and calculated minimum distance between the injection site and ROI (Equation 1). 
The cumulative distance in sequential pathways were also estimated (Equation 2). The 
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synaptic rank was estimated using the Granstedt´s formula (Equation 3) for PRV-152 
kinetics.     
ROI Acronyms 
mm from 
Bregma 
ROI center 
(AP/DV/ML) 
Auditory Cx Au -4.0 -4.5 / 5.0 / 6.5 
Anterior & 
Ventrolateral 
VA/VL -1.8 / -3.4 -2.1 / 6.0 / 1.6 
GP Internal EP -2.12 / -3.30 -3.1 / 8.0 / 2.8 
Subthalamic STN -3.60 / -4.30 -3.6 / 8.0 / 2.8 
GP External GP -1.30 / -3.30 -3.1 / 6.5 / 4.4 
Caudate CP 2.20 / -3.80 -2.3 / 6.0 / 5.4 
Medial 
Geniculate 
MGN -4.52 / -6.30 -6.3 / 6.0 / 3.8 
Inferior 
Colliculus 
IC -7.64 /-9.80 -7.6 / 5.0 / 1.8 
 
Table 6. Rostrocaudal brain segment assessed for ROI: Range distance from Bregma for 
each ROI and the reference coordinates for distances based on 3D brain reconstructions. 
4.3.8 Circuit reconstruction 
In order to evaluate the hypothesis of an auditory striatal circuit as a neuronal path 
from the auditory cortex to the caudatoputamen, the synaptic rank of the regions in the 
striatal pathway were compared to the sensory pathway. Thus, brain regions with direct 
projections to the auditory cortex should show eGFP expression concurrently with the 
MGN, while brain regions with indirect projections to the auditory cortex should be 
detected subsequently and in accordance with the eGFP expression in the inferior 
colliculus. The expression of eGFP in every region was measured by evaluating the 
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average cell counts within each ROI. Next, a heat map was created with the natural 
logarithm of the average cell counts to identify the TOD for each ROI. A logarithmic 
transformation was performed to correct for a left skewed distribution of the average cell 
counts (Equation 4), due to the subtle increase in cell counts in the initial rise of eGFP 
expression from 24 to 36 hours.  
Because the viral spread is mainly delayed by the recruitment of a new synaptic level, we 
assumed a linear relationship between TOD and synaptic level. Thus, the axonal distance 
traveled by virions accounts for the remaining variability on the estimation of the 
synaptic level (Equation 2). In this manner, regions at similar linear distance to the 
injection site would have equal synaptic level had the virus not spread through the 
neuronal projections. In contrast, a neuronal path would reveal different synaptic levels 
for ROI at equal distances from the injection site. Next, the TOD was used to estimate the 
synaptic rank (Equation 3). ROI were organized following the synaptic rank and grouped 
for the 24, 30 and 36 hour TOD. We evaluated with ANOVA the main and specific 
effects in the synaptic rank of these groups in order to differentiate primary and 
secondary projections to auditory cortex.  
Finally, 3D reconstructions were carried out. The virtual slides were then assigned a Z 
value according to the distance from bregma, which was estimate using the section count 
and the rat brain atlas as reference. Virtual slides of each brain were saved in a virtual 
image stack, and each stack was aligned using the contours and center of the sections. 
Virtual stacks were optimized for rendering in the 3D module by smoothing the 3D 
volumes for each contour. Volumes then were assigned a transparency percentage to 
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allow visualization of cellular markers. The 3D reconstructions of the eGFP expressing 
cells were color coded according to the type of projection (primary or secondary). A 
video using anaglyph rendering was recorded of each brain turning the reconstruction 360 
degrees on the Z-axis.  
4.3.9 Mathematics and equations 
Equation 1.                           
           
            
   
A: point of origin, B: target point, DV: dorso-ventral coordinate, ML: medio-lateral 
coordinate and AP: antero-posterior coordinate. 
Equation 2.                               
           
            
   
Equation 3.                                                                 
Equation 4.                                         
4.4 Results 
Our study evaluated the neuronal input of the auditory cortex to describe 
additional input pathways to the auditory sensory pathway. We explored the passage of 
PRV-152 through the circuit in a broad period of 72 hours to estimate the approximate 
TOD of the ROI.  
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4.4.1 Time of detection for regions of interest 
In this first study, we detected induced eGFP expression after 12 hours 
postinoculation in the thalamus (Figure 8A) and injection site (Figure 8B), which rapidly 
peaked around 48 hours in ROI at the third synaptic rank. The spread of PRV-152 
throughout the brain revealed brain regions that  express eGFP at the same time of the 
injection site (primary projections) and brain regions that showed a delay in the 
expression of eGFP (secondary projections). Therefore, in order to discriminate better the 
secondary input, we evaluated a period of 24 to 48 hours at shorter time intervals. We 
found a main effect of the TOD between 24 to 36 hours in the synaptic rank of ROI in the 
ipsilateral hemisphere (ANOVA F(2, 9): 16.93, p < 0.05) and contralateral hemisphere 
(ANOVA F(2, 9): 355.50, p < 0.05).  
 
Figure 8A. Cell expressing eGFP in the first synaptic rank; 12 hours 
postinoculation at 60x. Scale bar depicts 100 μm 
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Figure 8B. Injection site and ipsilateral cortex; 24 hours postinoculation at 40x. Scale bar 
depicts 400 μm 
4.4.2 Primary and secondary projections 
In the latter study, PRV-152 reached ROI in three main phases (Table 4). We 
compared the synaptic ranks of these phases to define the ROI of primary and secondary 
projections. The initial phase expressed eGFP at the same rate as the inoculation site. 
Thus, the ipsilateral auditory cortex and the thalamus show cell counts after 24 hours 
postinoculation (Table 4). The simultaneous induction of eGFP expression in the 
thalamus and the auditory cortex demonstrates direct thalamic input to the injection site. 
Thalamic projections appeared bilaterally in the VA/VL nuclei and MGN (Figure 8C-D). 
These initial projections correspond to a second synaptic rank in the sensory and striatal 
circuit, which denote the thalamo-cortical portion of the circuit. ROI detected at 24 hours 
have significantly lower synaptic ranks than the ROI detected at 30 and 36 hours (Table 
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4). In addition to these thalamic nuclei, PRV-152 also spread along the reticular nucleus 
showing sparse rostrocaudal expression.  
 
Figure 8C. Posterior projections from the injection site. Virtual slice at 20x in the -6.30 
mm level from bregma highlighting primary projections to auditory cortex after 24 hours 
of PRV-152 inoculation. Scale bar depicts 1.5 mm. White arrows show the bilateral 
labeling of MGN and auditory cortex. 
The second phase of cells expressing eGFP was detected in the ipsilateral entopeduncular 
nucleus, hippocampus and caudatoputamen (Figure 8E) at 30 hours postinoculation. The 
synaptic rank of these regions was statistically differentiable from regions detected in the 
first phase at 24 hours but their ranks did not differ from the regions detected in the third 
phase at 36 hours postinoculation (Table 4). Therefore, we considered the entopeduncular 
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nucleus and the caudatoputamen part of the secondary projections in the third synaptic 
rank. 
 
Figure 8D. Cells expressing eGFP in the striatum at 10x. Fluorescent micrograph at -1.8 
mm from bregma 36 hours postinoculation of PRV-152. Scale bar depicts 800 μm. White 
arrows show eGFP expressing cells. Stars depict fiber tracts.   
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Figure 8E. Anterior projections from the injection site. Virtual slide at 20x in the -3.6 mm 
level from bregma. Scale bar depicts 1.5 mm. Top right: White arrows depict a close-up 
of cells expression eGFP in the second and third synaptic level 30 – 36 hours 
postinoculation. Top left arrow signals the globus pallidus. Bottom right arrow shows 
eGFP cells in the mesencephalon. Arrow in the middle shows labeling in the 
entopeduncular nucleus. Scale bar depicts 800 μm. 
In the third phase, PRV spread bilaterally to the IC after 36 hours postinoculation. These 
neurons correspond to secondary projections of the sensory auditory pathway. Similarly, 
cells in the globus pallidus and subthalamic nucleus showed bilateral eGFP expression 
after 36 hours postinoculation (Figure 8E). These indirect projections in both pathways 
correspond to a third synaptic rank, which have statistically higher synaptic rank than 
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regions in the first phase (Table 4). Rostral projections in the third phase represent the 
striato-thalamic portion of the circuit. 
  0 24 30 36 42 48 Distance Synaptic 
Ip
s
ila
te
ra
l 
CxAud 0 5.0 4.5 5.9 3.1 7.3 0.0 1.2 
VA/VL 0 2.9 2.0 4.3 2.6 4.3 5.5 2.2 
Thalamic 0 2.7 3.1 5.2 2.9 5.0 4.5 2.3 
MGN 0 1.6 0.5 3.3 2.1 5.8 3.4 2.3 
Reticular 0 2.2 2.0 4.1 2.3 4.0 3.0 2.3 
Cortex 0 3.9 3.6 3.9 2.7 8.0 0.0 2.4 
EP 0 0.0 1.1 2.6 1.7 3.6 5.0 2.9 
Hippo 0 0.3 1.5 3.3 2.6 3.7 3.6 2.9 
CP 0 0.0 1.0 3.7 2.4 4.9 2.7 2.9 
IC 0 0.0 0.0 3.5 1.1 1.2 5.7 3.4 
STN 0 0.0 0.5 1.5 0.7 2.0 4.8 3.5 
GP 0 0.0 0.0 2.6 1.6 3.3 2.9 3.5 
C
o
n
tr
a
la
te
ra
l 
Reticular 0 2.3 0.8 3.9 2.1 3.9 10.4 2.1 
Hippo 0 1.3 0.5 3.3 2.3 3.6 10.2 2.1 
Thalamic 0 2.9 2.9 5.4 1.7 5.0 9.2 2.1 
VA/VL 0 1.8 2.2 4.3 1.8 3.8 8.5 2.2 
Cortex 0 0.7 2.1 4.1 2.7 5.3 13.0 2.6 
CP 0 0.3 1.1 3.3 2.1 4.3 12.1 2.7 
GP 0 0.0 1.5 3.0 1.9 3.1 11.1 2.7 
MGN 0 0.0 0.8 3.4 2.4 3.1 10.5 2.7 
CxAud 0 0.3 0.0 3.6 1.7 5.6 13.0 3.2 
EP 0 0.0 0.5 2.6 0.7 3.6 9.9 3.3 
STN 0 0.0 0.0 1.5 0.3 2.2 9.8 3.3 
IC 0 0.0 0.0 3.9 0.0 1.3 8.9 3.4 
 
Table 7. Logarithm of the average cell counts for brain regions detected from 24 to 48 
hours postinoculation. The top heat map corresponds to the ipsilateral hemisphere, and 
the bottom to the contralateral hemisphere. Heat maps contain the logarithmic 
transformation of the average cell counts for every brain region according to the time 
post-inoculation in hours (Top row). Heat maps color code the distribution of average cell 
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counts along all brain regions and post-inoculation times: Green: above 97.7%, Red: 
below 2.3% and Yellow: median, other colors correspond to in between values. Distance 
column shows the triangulated distance from the injection site to each ROI. Synaptic 
column has the estimated synaptic rank for each ROI. All ROI are listed in order 
according their synaptic rank (First column). 
 
Ipsilateral Hemisphere Contralateral Hemisphere 
F (2, 9) 16.93, p = 0.0009 F(2,9) 355.50, p = 0.0000 
 24 h 36 h  24 h 36 h 
30 h 
0.7833 
0.029 
 30 h 
0.55 
< 0.0001 
 
36 h 
1.35 
0.001 
0.5667 
0.213 
36 h 
1.175 
< 0.0001 
0.625 
< 0.0001 
 
Table 8. Comparison of the synaptic ranks between ROI detected at 24, 30 and 36 h. 
There is a main effect of TOD in the synaptic rank of ROI within each hemisphere. The F 
statistic and p values of the ANOVA are shown at the top row for each hemisphere. The 
comparisons of synaptic rank differences between postinoculation times are shown with p 
values adjusted with Bonferroni’s F test in corresponding cell. P values with statistical 
significance appear in bold case. In the ipsilateral hemisphere, the group detected at 24 h 
has lower synaptic ranks than ROI detected at 30 and 36 hours. However, there is no 
significant difference between the synaptic ranks of ROI detected at 30 and 36 h. In the 
contralateral hemisphere, synaptic ranks of all groups differ significantly. 
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4.5 Discussion 
The present work demonstrates the neuronal connectivity between the auditory 
cortex and the posterior aspect of the caudatoputamen. We used the synaptic rank derived 
from the PRV-152 detection throughout the rat brain to reconstruct the connectivity that 
impinges on the auditory cortex. Cells infected between 24 and 48 hours revealed the 
brain regions that send primary and secondary projections to the injection site.  
The directionality of the input to the auditory cortex (- 4.2 mm from Bregma) allow us to 
distinguish caudal projections of the auditory sensory pathway from rostral projections of 
a striatal origin. These initial retrogradely labeled projections simultaneously appeared in 
distinctive rostrocaudal portions of the thalamus in the MGN and the VA/VL respectively 
(Figure 8C). Such sources of direct thalamo-cortical input to the auditory cortex indicate 
signal integration of auditory processing at this segment of the temporal cortex. A diverse 
input to auditory cortex also implies that auditory perception involves multiple brain 
networks in addition to the sensory pathway of auditory modality.  
Cortical viral spread around the ipsilateral auditory cortex occurred after 36 hours 
postinoculation. The viral containment near the injection site up to a third synaptic rank 
may be due to the dense columnar network, which predominantly sends vertical 
projections between cortical layers or receive afferent projections from deep brain 
structures. As a result, less horizontal cortico-cortical projections are characteristic of the 
auditory (Happel et al., 2014).  
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The contralateral cortex was detected in the third synaptic rank after bilateral thalamic 
spread, which suggests a faster passage of PRV-152 across the middle line through the 
thalamus rather than via trans-callosal projections. This advocates for an important 
function of the thalamus in the integration of information between hemispheres and also 
defines the role of cortico-thalamic projections in coordinating auditory cortical input 
from other brain regions.  
The order of ROI following their synaptic rank differed in the contralateral hemisphere 
from the order in the ipsilateral hemisphere (Table 4).  This is most evident in the 
striatum where ipsilateral input to the ipsilateral thalamus reveals the entopeduncular 
nucleus as the relay nucleus that participates in the output of the basal ganglia (Atsushi, 
2007). In contrast, in the contralateral hemisphere the contralateral globus pallidus was 
detected earlier than the contralateral entopeduncular nucleus, which suggests that there 
are projections crossing the middle line at the striato-thalamic portion of the circuit.  
The difference in the hemispheric connectivity led us to focus in the ipsilateral 
hemisphere to distinguish the branching within the third synaptic rank. Thus, we 
interpreted the detection of the ipsilateral entopeduncular closely followed by the 
caudatoputamen and the subthalamic nucleus as secondary projections that may depict 
the convergence of the striatal pathways in the entopeduncular (Figure 8D).  If this is so, 
the detection of the ipsilateral globus pallidus at 36 hours may indicate the subsequent 
spread of PRV-152 through the ipsilateral indirect striatal pathway.  
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The delay in striatal induction of eGFP after the thalamic detection indicates that PRV-
152 spread through the rostral thalamus before reaching the striatum, which is consistent 
with a sequential passage of PRV-152 through the circuit. This finding demonstrates the 
presence of an auditory striato-thalamic-cortical neuronal circuit. Moreover, the detection 
of secondary projections from the posterior caudatoputamen suggests that the rostral 
thalamic path further connects with striatal pathways (Smith and Parent, 1986).  
We interpret the participation of the striatum in the input auditory networks as an 
auditory pattern generator involved in the perception of sound, which is congruent with 
the increased functional connectivity of the thalamus and caudatoputamen reported in the 
brain of patients with auditory hallucinations (Hoffman et al., 2011). Our findings present 
groundwork for the mechanism of intrinsic activation of the Au. This new description of 
the auditory CSTC pathway may explain striatal induced functional activation of the 
auditory cortex, and therefore provides novel insight into the pathophysiology of verbal 
auditory hallucinations.  
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Figure 9A.  
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Figure 9B.  
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Figure 9C.  
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Figure 8. 3D reconstruction of the eGFP expressing cells. Brain reconstructions after A: 
24 hours. B: 36 hours and C. 48 hours. The spread over time of PRV-152 through regions 
can be seen along these reconstructions. A) Shows eGFP expression in the injection site 
(white arrow) and initial expression in thalamic nuclei (yellow arrows). There are not 
cells labeled in the mesencephalon or striatum at this time. B) Shows farther extent of the 
eGFP expression in the injection site (white arrow), and initial expression in contralateral 
auditory cortex, as well as increased expression in thalamic regions. At this 
postinoculation time PRV-152 reaches the striatum  (See green arrow within the 
caudatoputamen in yellow) and the mesencephalon (See blue arrow towards the bottom 
of the brain.  C) Farther spread of PRV-152 towards  rostral and caudal regions. Cluster 
of cells can be seen in the thalamic nuclei (See magenta arrow for VA/VL labeling and 
ark blue arrow for MGN). Brain regions are shown as volume surfaces: Grey: Brain 
surface. White: diencephalon. derived structures Yellow: Caudatoputamen. Green: 
Hippocampus. Cells expressing eGFP are shown as dot markers. Direct projections: 
Bright red: Injection site. Red: Cortex. Yellow: Thalamus. Magenta: VA/VL nuclei. Dark 
blue: MGN. Indirect projections. Blue: Mesencephalon. Teal: Globus Pallidus. Green: 
Striatum. Grey: Inferior Colliculus. Orange: Hippocampus.     
4.6 Financial disclosures 
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CHAPTER 5 
DISCUSSION 
Our findings suggest that enhanced dopaminergic signaling through D2-like 
receptors in the posterior caudatoputamen enhance the activity of striatal circuits that 
impinge on the auditory cortex. The effects of dopamine in the brain can be evaluated in 
the cortex and striatum as these regions express dopamine receptors (Gerfen et al., 1990). 
However, modulation of information through the CSTC circuit by dopamine takes place 
at the cortico-striatal, thalamo-striatal, thalamo-cortical and striato-pallidal portion of 
these circuits. Thus, we will consider each synaptic level.  
Dopamine decreases the release of neurotransmitters acting at D2-like presynaptic 
receptors. For example, this effect may take place either in glutamatergic cortico-striatal 
or dopaminergic nigro-striatal projections (Bamford et al., 2004). As well as in other 
input projections into the caudatoputamen that releases other neuromodulators like 
serotonin. Such mechanism favors a down state of the SPNs of the striatum silencing the 
output release of glutamate from the thalamus to the cortex.  
It is important to note that the release of dopamine has a positive effect on the output 
flow of the direct and indirect striatal pathways at the thalamic level despite the different 
effects of dopamine on SPNs modulation. While the glutamatergic signal from cortex 
may activate or inhibit the striatal pathways, the role of the activation of postsynaptic 
dopamine receptors is going to increase the firing probability in the thalamus (Bamford et 
al., 2004). In this manner, the specific action of a co-infusion of D2-like receptor 
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antagonist reducing the effects on cortex of excessive local dopamine must be 
postsynaptic; otherwise, the activation of cortex would not be blocked. Therefore, our 
finding of the alleviation of dopamine-induced auditory cortical activity is interpreted as 
a postsynaptic D2-like receptor effect.  
Another portion of the pathway that may project to the posterior portion of the 
caudatoputamen consists of thalamo-striatal projections. In this case, the input from the 
thalamus to the striatum may inhibit the activity of the auditory related circuits (Gerfen 
and Surmeier, 2011). These projections are glutamatergic and appear to modulate striatal 
activity through cholinergic and GABAergic interneurons in the striatum (Surmeier et al., 
2007). Thus, thalamo-striatal input generates a pause in the activity of SPNs by acting on 
cholinergic interneurons; specifically, at presynaptic M2 receptors. Furthermore, the 
effect of thalamo-striatal projections on D2R expressing SPNs may produce an enhanced 
release of GABA by means of cholinergic response of M1 presynaptic receptors.  Taking 
this into account, the effect of the thalamic feedback to the striatum inhibits activity in the 
globus pallidus. Such findings are consistent with our finding that the D2-like receptor 
antagonist acts postsynaptically and decreases the output of the striatum because the 
effects of thalamo-striatal input on cholinergic cells set the striatal network into a biased 
state towards D2 activation (Ding et al., 2010).  
Enhanced dopamine D2-like receptor transmission on thalamo-cortical glutamatergic 
projections has been reported in an animal model of schizophrenia (Chun et al., 2014). In 
this Drd2 over expression model, D2-like receptors are upregulated affecting the 
thalamo-cortical release of glutamate. Although our model did not assess the effects of 
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dopamine on the thalamus, this disruption of transmission at the thalamo-cortical level 
demonstrates the neuronal connectivity of the thalamus and the auditory cortex, and 
offers a specific pharmacological model that may related to auditory activation.  
The effects of dopamine on striato-pallidal projections has not been specifically evaluated 
as most of the dopaminergic basal ganglia input enters at the striatum; however, 
dopamine release at various levels of the striatal pathways may offer scenarios of 
neuroplasticity that change the activity of CSTC loops. The fluctuations in the 
symptomatology of psychotic syndromes may be produced by the involvement of 
portions of these circuits; hence, striatal plasticity may facilitate or diminish cortical 
activity. Thus, producing enhanced activation as auditory hallucinations or decreasing 
function as negative symptomatology. In this manner, the neuroanatomical location of the 
excessive dopamine transmission defines the spectrum of symptoms according to the 
function carried out by those neurons.  
Laminar analysis of the auditory cortex after excessive dopamine in the caudatoputamen 
demonstrated activation of input layers III & IV and activation of the cortical segment. 
The mechanism that enhances auditory cortical activity may be generalized to other 
cortical regions that involve specific CSTC loops as modulators of cortical activity.  
In the auditory system, associative cortices responsible for language like the left superior 
temporal gyrus and left inferior parietal area could be activated by aberrant function of 
CSTC circuits generating manifestations of verbal auditory hallucinations (Lennox et al., 
2000, Bentaleb et al., 2002). In mammals the auditory cortex maintains a tonotopic 
  84 
organization derived from the sensory system (Barton et al., 2012).  The region activated 
by dopamine seems to be located posterior to a region of primary auditory sensory input, 
suggesting that this portion of the auditory cortex may be an associative region. However, 
the target for the injection of PRV-152 cover a wider area; therefore, producing effects in 
a striatal and sensory circuits.  
Correlating the results of the pharmacological and the neuroanatomical studies, the CSTC 
loops seem to play an important role interconnecting different cortical regions with a 
longer reach of connections than cortico-cortical pathways. This has enormous 
repercussions on integrative functions as the primary cortex receives the sensory input, 
these CSTC loops submit that information through acquired patterns in the basal ganglia 
that feedback cortical regions with the relevant interpretation of the signal. Such filtering 
of information is part of the ability to select and recognize sensory information, which is 
altered in patients with psychosis.  
Although our laminar analysis did not account for the interspersed location of the primary 
and secondary cortices along the rostrocaudal axis. A better differentiation of the laminar 
activation can be expected if this factor was considered in future studies. A clear step 
forward is the description of laminar activation patterns in Happel, 2010 where dopamine 
produced a sustained sensory cortical activation through positive recurrent feedback in 
layer II and IV after cortical distal stimulation. In this study, the cortical depth was 
divided into superficial, input and output layers and the electrical activity was measure 
after stimulation in the neighbored areas. In this manner, cortico-cortical connections and 
recurrent connections were assessed showing that the farther the stimulation the more 
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likely cortical regions are connected through recurrent efferent circuits. In contrast, the 
closer cortical regions are, the connections seem to reach recording electrode through 
cortico-cortical connections.  
The metabolic activation signaled by increased expression of zif268 mRNA represents a 
change in transcription, and therefore a profound effect on neuronal activity. These 
changes are related to alteration in neuronal plasticity like induction of dendritic growth 
or long term potentiation of synapses, which are dependent on glutamatergic release. In 
this manner, the results of our pharmacological studies represent a change in the 
neuroplasticity of these circuits.   
The scenario where different synaptic levels can be affected by neuromodulators in 
recurrent efferent cortico-striatal loops requires further study of the interactions at each 
level to dissect the specific effects of dopamine and the function of every group of 
projections. Further studies are also necessary to clear the complex nature of 
interneuronal connections onto spiny projecting neurons, and the different network 
characteristics at every synaptic level.  
More detail analysis can be done on the laminar assessment to specify the presence of 
granular or dysgranular layers. This will provide more accurate measures of the input 
layers in the cortex.  
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5.1 Conclusion 
Our description of an auditory pathway where known affected brain regions and 
specific attenuation effects of dopaminergic neurotransmission coincide to regulate the 
activity of columnar auditory cortical areas offers a first step in the description of 
recurrent efferent cortico-striatal loops and provides insight to the affected neuronal 
connectivity related to psychotic symptoms. 
The implications for aberrant modulation of CSTC circuits in the integration of 
information between different brain regions may explain the broad involvement of 
various brain functions in psychotic syndromes. Furthermore, dopaminergic transmission 
can modulate corticostriatal projections at different levels of these circuits, which 
provides more substrates for the generation of psychosis. However, our paradigm suggest 
the most likely region where dopamine affects CSTC circuits to be the striatum. The 
therapeutic effects of D2-like receptor antagonist and the evidence from functional 
studies on the caudate nucleus favor the idea of dysconnection at this portion (Stephan et 
al., 2006).  
When considering the clinical manifestations of psychosis, our results relate to the 
circuits relevant to auditory function. Nonetheless, similar mechanisms of 
neuropathology might produce other symptomatology when affecting different brain 
regions. Perhaps, rostral recurrent efferent circuits are involved in the cognitive 
symptoms of psychosis. Similarly, caudal recurrent efferent circuits might be related to 
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visual hallucinations. Negative symptoms respond to different therapeutics, and while 
correlated to neurological detriment, this symptomatology may be cause by other 
mechanisms or produce as fluctuations in the function of CSTC circuits decreases the 
activation of different cortical areas.  
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